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ABSTRACT 
 
Prolonged periods of reduced mechanical loading lead to physiological changes 
such as a reduction in muscle mass and strength. These morphological and functional 
changes are allowed to take place to regulate muscle mass, metabolic demand, and 
availability of the amino acid pool. Dysregulation of a number of cell signaling 
pathways have been proposed as triggers of unloading-induced atrophy including Ca2+, 
growth factors (e.g., IGF-1), heat shock proteins, and reactive oxygen species (ROS). 
ROS are causal in key disuse atrophy signaling events such as sarcolemma dislocation of 
nNOSµ and activation of the atrophy-inducing transcription factor FoxO3a. 
Upregulation of the Nox2 isoform of NADPH oxidase has been implicated in the disuse-
associated increase in ROS production. Evidence indicates that activation of angiotensin 
II type 1 receptor (AT1R) is an upstream event leading to Nox2 complex formation and 
activity.  
In the current study, we used an AT1R blocker (losartan) to test the hypothesis 
that AT1R activation is an upstream signaling event driving Nox2 complex activity, 
nNOSµ dislocation, FoxO3a activation, and thus the slow-to-fast fiber type shift and 
atrophy in the unloaded soleus. Rats were divided into 4 groups: ambulatory control 
(CON), ambulatory + Losartan (40 mg/kg/day) (CONL), 7-days hindlimb unloaded 
(HU), and HU + Losartan (HUL). We report that administration of losartan attenuated 
unloading-induced phenotypic alterations in the soleus muscle, including the shift in 
fiber type and reductions in muscle fiber cross-sectional area (CSA). Losartan 
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administration ameliorated increased ROS levels and the upregulation and activity of 
Nox2 following unloading. Furthermore, AT1R blockade during unloading mitigated 
nNOSµ dislocation from the sarcolemma. In addition, losartan treatment during disuse 
offered significant protection against the increase in nuclear localized FoxO3a. We 
conclude that AT1R attenuates disuse atrophy by inhibiting Nox2 signaling, thereby 
lessening the extent of nNOSµ dislocation, and activation of the pro-atrophic 
transcription factor FoxO3a. 
Our findings identify important downstream effects of AT1R activation during 
mechanical unloading-induced atrophy. Furthermore, these data provide support for the 
usage of the FDA-approved AT1R blocker, losartan, as a treatment to mitigate the 
effects of disuse atrophy that occur during instances such as prolonged bed rest, limb 
casting, and spaceflight. 
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CHAPTER I  
INTRODUCTION 
 
Loss of skeletal muscle mass results in muscular weakness, which negatively 
impacts quality of life. Skeletal muscle wasting occurs as a comorbidity to chronic 
diseases, as well as in response to prolonged periods of disuse. In the absence of disease, 
mechanical unloading or reduced loading, such as limb immobilization, bed rest, or 
exposure to microgravity, result in muscle atrophy. Although great strides have been 
made in recent years towards unraveling the molecular complexities involved in the 
atrophic process, the fundamental causes of altered skeletal muscle proteostasis remain 
uncertain. 
Seeking further understanding of the mechanistic and metabolic pathways 
involved in disuse atrophy and approaches to reduce, delay, or prevent this effect is of 
great importance. However, the etiology of disuse atrophy is poorly understood. 
In order to identify and/or develop therapeutic interventions to effectively mitigate 
disuse muscle atrophy requires knowledge of the signaling pathways involved in the 
regulation of protein synthesis and degradation in skeletal muscle cells. Accumulating 
evidence indicates that elevated production of reactive oxygen species (ROS) plays a 
critical role in altering the pathways involved in synthesis and degradation. Indeed, over 
the last quarter century, undeniable evidence indicates that increased ROS production 
contributes to disuse-induced skeletal muscle atrophy (Kondo et al., 1991; Lawler et al., 
2003; Powers et al., 2007).  
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 In the following chapters, we will focus on disuse atrophy as well as the roles 
and regulation of increased ROS production promoting muscle wasting. Chapter II will 
provide an overview of protein synthesis and protein degradation mechanisms and 
pathways involved in disuse atrophy. In addition, we will introduce the various sources 
of ROS along with evidence that ROS production plays a critical role in the regulation of 
both synthesis and degradation pathways. Furthermore, we will provide evidence 
implicating altered neuronal nitric oxide synthase (nNOS) localization as a critical event 
during disuse atrophy, which appears to occur in response to elevated levels of ROS. 
Chapter III is comprised of an original study investigating a potential upstream 
molecular signaling event driving the production of NADPH oxidase isoform 2 (Nox2)-
derived ROS during disuse atrophy. We previously reported that the sarcolemma-
localized Nox2 plays a contributory role to disuse atrophy incurred during rodent 
hindlimb unloading (Lawler et al., 2014); however, very little is understood concerning 
the regulation of Nox2 as a source of ROS in skeletal muscle, let alone during disuse 
atrophy. Clues from a variety of tissue types implicate ligand activation of angiotensin II 
type I receptor (AT1R) as an upstream signaling event promoting activation of Nox2 
(Cabello-Verrugio et al., 2012a; Balakumar & Jagadeesh, 2014). However, whether 
AT1R activation leads to Nox2 activation during hindlimb unloading-induced atrophy is 
unknown. Therefore, we sought to elucidate the role of AT1R – Nox2 signaling in the 
rodent hindlimb unloading model of disuse.  
A concluding chapter will provide a summary and conclusion of our findings. 
We will tie-in our novel observations from Chapter III with those discussed in Chapter 
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II. Finally, we will discuss the relevance of our pre-clinical research and potential 
integration into a clinical context. 
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CHAPTER II  
LITERATURE REVIEW: ROS AND NNOS IN THE REGULATION OF 
DISUSE-INDUCED SKELETAL MUSCLE ATROPHY 
 
2.1 Introduction 
Skeletal muscle plays a significant role in our overall health, survival, and our 
quality of life. It comprises about 40% of the total body mass and is a vital component to 
basic biological functions such as metabolism, respiration, and locomotion. 
Characterized by its highly dynamic and adaptable nature, skeletal muscle contains the 
ability to respond to a variety of stressors to alter its size and function. For example, 
increasing the workload and mechanical load will result in skeletal muscle hypertrophy, 
whereas lessening or removing the load will result in muscle atrophy (Goldberg et al., 
1975). Skeletal muscle atrophy is also a response to chronic disease (i.e. cachexia, 
congestive heart failure, aging). The physiological impact of muscle atrophy is 
characterized by muscle weakness, fatigability, and increased mortality. Therefore, 
uncovering the critical molecules, proteins, and signaling cascades that regulate skeletal 
muscle atrophy is an active area of biological and physiological research. While the cell 
signaling underlying skeletal muscle atrophy across wasting phenomena remains 
mysterious, there has been encouraging progress in recent years. 
 The reduction of mechanical load or complete unloading of skeletal muscle is 
often termed ‘disuse’. Disuse-induced skeletal muscle atrophy results in physiological 
changes such as a reduction in muscle mass and strength. The extent of disuse-induced 
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skeletal muscle atrophy depends on several factors such as age, degree of mechanical 
unloading, and the function and fiber type composition of the affected muscle. As 
previously mentioned, skeletal muscle wasting also occurs as a comorbidity to chronic 
disease, and has been observed in pathologies such as cancer, congestive heart failure, 
diabetes, chronic obstructive pulmonary disease (COPD), severe burn injury, 
inflammatory bowel disease, etc. Muscle wasting in these pathologies is partly due to 
muscle disuse, but overriding effectors include oxidative stress, inflammatory signaling 
and cytokines. Whether atrophy is primarily due to disuse or as comorbidity with 
disease, there are common atrophic signaling events that stimulate reduction in muscle 
fiber cross-sectional area (CSA), decreased muscle protein content, and decreased mass. 
In addition, atrophy promotes a reduction in capillary density, architectural disruptions 
of the myofiber, phenotypic alterations in fiber type, reduction in force production, and 
eventual weakness that corresponds with easily fatigable muscles. Indeed, it is skeletal 
muscle weakness and fatigability that are the major factors impacting the impairment in 
the quality of life of affected individuals. 
 As mentioned above, prolonged periods of disuse due to bed rest, limb 
immobilization, denervation, or hindlimb unloading result in skeletal muscle atrophy. 
Concomitant with reduction in muscle mass, disuse-induced atrophy also results in a 
shift in fiber type from the slower oxidative phenotype to the faster glycolytic 
phenotype. Skeletal muscle atrophy is due to an imbalance between synthesis and 
breakdown of muscle protein. While the majority of the published studies have focused 
on protein degradation, the impact of decreased protein synthesis is critical to the 
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wasting process. Recent papers have emphasized cross-talk between protein degradation 
and protein synthesis, centered around an Akt – FoxO axis. The impact of disuse-
induced protein degradation is a complex process, with new players and pathways 
having been identified in recent years. Major roles in the degradation process are taken 
on by the ubiquitin proteasome pathway (UPP), caspase-3 / calpains, and the autophagic-
lysosomal pathway. 
 There is direct evidence that elevation of oxidative stress occurs during disuse, 
and may serve as a trigger to atrophic signaling by promoting muscle protein 
degradation and reducing muscle protein synthesis. However, the exact sequence of 
events from the onset of disuse to the increased production of reactive oxygen species 
(ROS) and subsequent atrophic signaling has not yet been established. In this review we 
will provide (1) an overview of the various experimental models of disuse-induced 
atrophy, followed by (2) an overview of synthesis and degradation mechanisms and 
pathways involved in disuse-induced atrophy. Then we will introduce the (3) evidence 
that ROS production plays a critical role during disuse-induced atrophy, followed by (4) 
the regulation of neuronal nitric oxide synthase (nNOS) localization and activity in 
response to disuse. 
2.2 Models of Disuse 
Disuse-induced atrophy has been investigated in several different models in both 
humans and rodents. Due to the invasiveness of procuring muscle samples from subjects, 
rodent models of disuse atrophy are often used to study the tissue adaptations, cellular 
mechanisms and signaling cascades involved in disuse atrophy. A variety of models of 
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disuse atrophy have been developed to mimic the various clinical atrophy-inducing 
events. For instance, the rodent model of limb immobilization is limb casting. Another 
common model of disuse is hindlimb unloading by way of rodent tail suspension, a 
common experimental model used to mimic the physiological response to prolonged 
periods of bed rest or spaceflight. In addition, animal models have been used to 
investigate the impact on skeletal muscle due to spinal cord injuries or denervation. A 
common model used to examine disuse of the respiratory muscles (e.g., diaphragm) is 
the mechanical ventilation rodent model. 
While there are a number of animal models of disuse-induced skeletal muscle 
atrophy, human paradigms of disuse are often used for research purposes as well, despite 
the invasiveness. For example, human models of limb immobilization (i.e., casting or leg 
brace), prolonged bed rest, and unilateral lower limb suspension (ULLS; e.g., 
immobilizing one leg and walking with crutches or knee walker) are used to examine 
inactivity-induced atrophy in patients. 
2.3 Mechanisms of Disuse-Induced Skeletal Muscle Atrophy 
2.3.1 Decreased Protein Synthesis and Elevated Protein Degradation 
To maintain a basal level of skeletal muscle mass, a balance between protein 
synthesis and protein degradation is necessary. In recent years, there has been a 
significant on-going debate regarding the roles of protein synthesis and degradation 
during disuse atrophy. This is partly due to the different models (humans vs. rodents) 
that have been used. In general, the major difference between human and rodent disuse 
models concerns the relative rate of atrophy, with atrophy occurring at a much faster rate 
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in rats than in humans (Phillips et al., 2009), although muscle fiber-type plays a 
significant role. While most of the available data indicates that there is an initial drop in 
synthesis rates along with an increase in rates of degradation, there is a contrasting view 
that in humans, disuse atrophy occurs primarily in response to reduced synthesis rates 
(Phillips et al., 2009). This is derived from human studies that have found a reduction in 
synthesis, while data regarding breakdown is inconsistent (Ferrando et al., 1996; Urso et 
al., 2006; Chen et al., 2007; de Boer et al., 2007; Glover et al., 2010) and, in some 
instances, the methodology is deemed questionable or unreliable (Tesch et al., 2008). 
Data inconsistencies are due in part to the difficulties associated with measuring rates of 
protein degradation in humans, with most of the data collected relying on the expression 
of genes associated with specific protein degradation pathways. Obviously, additional 
studies are warranted to determine if reductions in protein synthesis are the driving force 
of atrophy or if there is simply a lack of data from human disuse studies. For a glimpse 
into this on-going debate of decreased synthesis vs. increased degradation, refer to a 
recent Journal of Physiology Crosstalk series (Phillips & McGlory, 2014; Reid et al., 
2014). 
Accumulating evidence indicates that disuse-induced skeletal muscle wasting is 
due to a combination of the reduction in the rate of protein synthesis and an elevation in 
protein degradation. For instance, in the hindlimb unloading model skeletal muscle 
protein synthesis rates were reduced within the first 5 hours of disuse (Thomason et al., 
1989), and within 48 hours the decreased synthesis rate levels off at a steady-state 
(Thomason et al., 1989). Prolonged periods of disuse are known to lead to an increase in 
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protein degradation (Bodine et al., 2001). However, rapid increases in proteolysis have 
been reported during mechanical unloading as well (Arbogast et al., 2007; Schiaffino et 
al., 2013). Together, those data indicate that the loss of skeletal muscle protein during 
disuse is most likely the outcome of declining synthesis rates and elevated degradation 
rates, with the latter playing the dominant role (Schiaffino et al., 2013; Egerman & 
Glass, 2014).  
The key degradation components that promote skeletal muscle wasting include 
ubiquitin proteasome pathway (UPP), caspase-3 / calpains, serine protease, and 
autophagy-lysosomal pathways (Powers et al., 2007; Schiaffino et al., 2013). Primary 
targets of degradation during disuse atrophy include myofibrillar proteins, although 
sarcoplasmic proteins are also degraded (Munoz et al., 1993). 
2.3.2 Disuse Atrophy Signaling Cascades 
A variety of physiological stimuli trigger skeletal muscle atrophy. For example, 
atrophy that occurs as a comorbidity with chronic disease is considered to be caused by 
increased levels of pro-inflammatory cytokines, endotoxins, glucocorticosteroids, and 
tumor-derived factors (Schiaffino et al., 2013; Egerman & Glass, 2014). On the other 
hand, disuse-induced skeletal muscle atrophy occurs through a reduction in mechanical 
tension (Kandarian & Stevenson, 2002) and elevated levels of oxidative stress (Powers 
et al., 2007).  
 In part, skeletal muscle atrophy can occur as the result of blunting the anabolic 
insulin-like growth factor-1 (IGF-1) signaling pathway. Activation of IGF-1 requires 
signaling through the IGF receptor (IGFR) and the insulin receptor substrate-1 (IRS-1), 
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which leads to phosphorylation of phosphatidylinositol-3 kinase (PI3K).  Active PI3K 
then phosphorylates phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5- 
trisphosphate in the sarcolemma, creating a binding site for Akt. Activation of Akt leads 
to active phosphorylation of mammalian target of rapamycin complex 1 (mTORC1). 
mTORC1 regulates synthesis through phosphorylation and activation of p70S6K and 
downstream inhibition of eukaryotic translation initiation factor 4E-binding protein 1 
(4E-BP1). Data from numerous studies support the role of the IGF-1 / PI3K / Akt / 
mTORC1 signaling cascade in the regulation of skeletal muscle hypertrophy and atrophy 
(Schiaffino et al., 2013; Egerman & Glass, 2014). For example, IGF-1 resistance has 
been reported after 14 days of hindlimb unloading in skeletal muscle of rats (Allen et al., 
1997). However, injections of growth hormone and IGF-1 during unloading have limited 
effect, possibly due to up regulation of IGF-1 binding proteins (Wittwer et al., 2002). In 
addition, activation of Akt / mTORC1 and the downstream effectors is repressed during 
hindlimb immobilization and hindlimb unloading (Hornberger et al., 2001; You et al., 
2010; Kelleher et al., 2013). A critical event in this signaling cascade is the activation of 
Akt, which is suggested to be a transition point between hypertrophy and atrophy 
(Schiaffino et al., 2013; Egerman & Glass, 2014). 
 Degradation pathways in skeletal muscle include the ubiquitin proteasome 
pathway (UPP), calcium-dependent caspase-3 / calpains, serine protease, and the 
autophagy-lysosomal pathway (Powers et al., 2007; Schiaffino et al., 2013). Calpains 
are thought to initiate proteolysis via unzippering of the Z-disc (Ferreira et al., 2009; 
Salazar et al., 2010; Talbert et al., 2013a) during periods of disuse, while the primary 
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degradation pathway is believed to be the UPP (Solomon & Goldberg, 1996; Taillandier 
et al., 1996). Recently, autophagic-lysosomal proteins (Taillandier et al., 1996; Talbert 
et al., 2013b) have been cited as contributory to unloading-induced proteolysis.  
As the major proteolytic pathway during disuse atrophy, the UPP serves to 
breakdown myofibrillar and sarcoplasmic proteins in muscle fibers. Distinct components 
of the UPP include the E1, E2, and E3 ubiquitin ligases. E1 ubiquitin ligases activate 
ubiquitin, the activated ubiquitin is transferred to the E2 conjugating ligase, and the E3 
ubiquitin ligases regulate the transfer of the ubiquitin to the targeted protein. Two critical 
tissue-specific E3 ubiquitin ligases, MuRF1 and MAFbx/Atrogin-1, are upregulated in 
response to a variety of atrophy-inducing events. Bodine et al. (2001) found that in 
response to various models of disuse (i.e., hindlimb unloading, limb immobilization, and 
denervation), transcription of MuRF1 and MAFbx/Atrogin-1 were increased (Bodine et 
al., 2001). Under resting conditions in skeletal muscle these genes are expressed at 
relatively low levels; however following reductions in mechanical load, expression of 
these genes is quickly induced. Expression of both MuRF1 and MAFbx/Atrogin-1 is 
rapidly elevated in numerous models of atrophy and suggested to significantly contribute 
to the initiation of atrophy (Bodine & Baehr, 2014).  
2.3.3 FoxO and NF-κB Signaling 
 Expression of both MuRF1 and MAFbx/Atrogin-1 are regulated by a variety of 
transcription factors, including members of the forkhead box O transcription factor 
family (FoxO1 and FoxO3a), nuclear factor kappa B (NFκB) transcription factors (p50 
and Bcl3), and the glucocorticoid receptor (GR) (Sandri et al., 2004; Sacheck et al., 
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2007; Waddell et al., 2008; Wu et al., 2011). During prolonged periods of disuse 
alterations in the activity of glucocorticoids has not been shown, thus elevated 
expression of MuRF1 and MAFbx/Atrogin-1 are not likely due to GR signaling (Watson 
et al., 2012).  
However, during various atrophy-inducing states, including disuse, elevated 
expression of FoxO1/3a has been observed (Lecker et al., 2004; Sacheck et al., 2007; 
Senf et al., 2008) along with FoxO1/3a transcriptional regulation of MuRF1 and 
MAFbx/Atrogin-1 (Sandri et al., 2004; Stitt et al., 2004; Waddell et al., 2008). 
Cytoplasmic dephosphorylation of FoxO proteins leads to nuclear translocation where 
they function as transcription factors acting to suppress growth and promote apoptosis 
(Ramaswamy et al., 2002). FoxO activation can be regulated upstream by Akt, which 
can phosphorylate multiple sites on FoxO to prevent its nuclear translocation (Brunet et 
al., 1999; Sandri et al., 2004; Latres et al., 2005). However, findings from human studies 
indicate there may be a dissociation between Akt signaling and synthesis / degradation, 
leaving the exact mechanism of FoxO1/3a regulation unclear (Marimuthu et al., 2011).  
 As previously mentioned, NFκB-associated transcription factors (Bcl3 and p50) 
have been shown to upregulate MuRF1 and MAFbx/Atrogin-1 in response to mechanical 
unloading (Jackman et al., 2013). In the unloaded rat soleus, a significant increase in the 
nuclear concentration of NFκB / Inhibitor of κ B (IκB) proteins p50, c-Rel, and Bcl3 was 
observed; however, activation of the canonical NFκB dimers p50-p65 were not found to 
be significantly activated (Hunter et al., 2002). Kandarian’s group found that p50 and 
Bcl3 serve as transcription factors for MuRF1 and MAFbx/Atrogin-1 during rodent 
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hindlimb unloading, and knock out of each transcription factor led to sparing of the 
muscle (Hunter & Kandarian, 2004).  
Recent data from the Kumar and Kandarian research groups indicates that NFκB 
signaling during disuse may be regulated in part by activation of the fibroblast growth 
factor-inducible 14 (Fn14) receptor. Fn14 transcription and protein levels are induced in 
skeletal muscle during immobilization, hindlimb unloading, and following denervation 
(Mittal et al., 2010; Wu et al., 2011). In contrast, remobilization or resistance exercise 
both lead to a reduction in Fn14 transcription (Mittal et al., 2010). Those data suggest a 
mechanosensitive role for Fn14 and its downstream NFκB signaling.    
 While FoxO1/3a and NFκB transcription factors have received much attention 
related to disuse-induced atrophy signaling, they are not the only mediators involved. 
Recent work by the Adams research group has unveiled two novel transcription factors 
upregulated with disuse: activating transcription factor 4 (ATF4) (Ebert et al., 2012; Fox 
et al., 2014) and the tumor suppressor p53 (Fox et al., 2014). Using a mouse model, 
Ebert et al. (2012) knocked out the ATF4 gene, consequently preventing expression of 
the growth-arresting protein Gadd45a, and observed a muscle sparing effect following 3 
days of limb immobilization but not 7 days of immobilization (Ebert et al., 2012). In a 
follow-up study, their group reported increased expression of p53 with immobilization 
(Fox et al., 2014). Muscle fiber atrophy even occurred in the absence of ATF4, while 
simultaneous forced expression of both factors exacerbated disuse atrophy (Fox et al., 
2014). Their data suggest that ATF4 and p53 signal through independent, yet additive, 
routes during skeletal muscle atrophy by stimulating p21 (Ebert et al., 2012; Fox et al., 
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2014). Interestingly, neither ATF4 nor p53 act as transcription factors for MuRF1 or 
MAFbx/Atrogin-1 (Ebert et al., 2012; Fox et al., 2014), indicating that their 
transcriptional regulation of atrophy is through alternative ubiquitin ligases or other 
mechanisms. These novel data support the notion that attenuation of muscle atrophy is 
likely accomplished in several phases, and that multiple transcription factors participate 
in the regulation of the atrophic process. 
2.3.4 Novel Disuse-Induced E3 Ubiquitin Ligases 
As indicated in the above paragraph, regulation of atrophy is not due to 
upregulation of a single transcription factor, nor upregulation of a single E3 ubiquitin 
ligase. In recent years, independent investigators have identified novel E3 ligases that 
are linked to regulation of skeletal muscle during catabolic states. For instance, 
expression of a HECT domain ubiquitin ligase referred to as Nedd4-1 was increased in 
skeletal muscle in response to denervation (Batt et al., 2006) and hindlimb unloading 
(Koncarevic et al., 2007). In addition, the muscle ubiquitin ligase of SCF complex in 
atrophy – 1 (MUSA1) is another recently discovered F-box E3 ubiquitin ligase. 
Overexpression of MUSA1 promoted muscle loss, whereas RNA interference led to 
sparing of muscle mass (Sartori et al., 2013; Milan et al., 2015).  
Moreover, atrophic signaling that leads to FoxO1/3a activation has been linked to 
increased expression of the mitochondrial E3 ligase 1 (Mul1) (Lokireddy et al., 2012). 
Mul1 participates in the promotion of mitochondrial fragmentation, depolarization, and 
mitophagy, all of which are associated with mitochondrial dysfunction (Lokireddy et al., 
2012).  
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Examination of the negative regulation of IGF-1 signaling has unveiled new E3 
ubiquitin ligases: Cbl-b and mitsugumin 53 (MG53 or TRIM72). For instance, Cbl-b has 
been observed to negatively regulate IGF-1 signaling during prolonged periods of 
unloading (Nakao et al., 2009). MG53 targets the insulin receptor for degradation and 
subsequently ubiquitinates IRS-1 in skeletal muscle from mice with metabolic syndrome 
(Song et al., 2013).  
These are just a few of the E3 ligases that have been connected or possibly have 
connections to disuse atrophy. Advances in techniques, antibodies, genetic models, 
epigenetics, etc. will further our understanding of the players and cascades involved in 
atrophy signaling. 
2.4 Reactive Oxygen Species (ROS) Production in Skeletal Muscle During Disuse-
Induced Atrophy 
2.4.1 Oxidative Stress and Disuse-Induced Skeletal Muscle Atrophy 
It has been 25 years since the first study connecting elevated levels of oxidative 
stress to disuse-induced skeletal muscle atrophy (Kondo et al., 1991). Kondo et al. 
(1991) found that immobilization-induced atrophy in rats was associated with increased 
oxidative stress. Furthermore, the antioxidant properties of vitamin E attenuated the 
degree of atrophy (Kondo et al., 1991). Since their novel findings were published, 
supporting data has accumulated suggesting the role/s of specific oxidant sources and 
antioxidants during the atrophic process. Furthermore, the manipulation of which can 
lead to muscle sparing effects during disuse (Lawler et al., 2003; Min et al., 2011; 
Lawler et al., 2014). Altogether, the growth and progress of this field of interest has 
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driven the investigative efforts examining the roles of ROS, redox modifications, and 
associated signaling events that lead to skeletal muscle atrophy during prolonged periods 
of disuse. 
2.4.2 ROS Production in Skeletal Muscles During Prolonged Periods of Disuse  
Oxidative stress occurs when there is an imbalance between pro-oxidants and 
antioxidants, with the imbalance favoring the build-up of oxidized molecules within the 
cell or tissue (Lawler et al., 2016). An ever-growing body of evidence indicates that 
disuse leads to elevated levels of oxidized proteins and lipids within skeletal muscle. 
Increased cellular concentrations of oxidized proteins and lipids, which are essentially 
damaged, are the result of elevated activities of pro-oxidant sources and ROS, as well as 
a reduction in the antioxidant capacity of the myofiber (Lawler et al., 2016). To 
investigate this phenomenon, researchers have focused on the pro-oxidant sources within 
skeletal muscle fibers. Accumulating evidence suggests that skeletal muscle disuse leads 
to ROS production from various sources, including the mitochondria, xanthine oxidase 
(XO), and NADPH oxidase (Nox). 
Strong evidence from mechanical ventilation and hindlimb immobilization 
studies indicates that a primary source of ROS during skeletal muscle disuse is the 
mitochondria (Min et al., 2011; Talbert et al., 2013b; Hudson et al., 2015). For instance, 
mitochondrial release of hydrogen peroxide is increased more than 2-fold in the soleus 
and plantaris from rodents that endured 2 weeks of hindlimb immobilization (Min et al., 
2011). However, it is currently unknown if both populations of skeletal muscle 
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mitochondria, subsarcolemmal and intermyofibrillar, contribute to this elevation in ROS 
production.  
In the series of pioneering work from Kondo et al. in the early 1990’s, Kondo 
and colleagues suggested that XO may be the primary source of ROS in myofibers 
during disuse (Kondo et al., 1993). Since then, however, data inconsistencies have been 
reported concerning XO and disuse. Evidence from mechanical ventilation experiments 
indicates that XO plays a significant role in oxidative injury and contractile dysfunction 
during periods of disuse (Whidden et al., 2009). In agreement, XO inhibition blunted the 
severity of disuse-induced contractile dysfunction caused by hindlimb unloading, even 
though XO inhibition did not spare the soleus muscle from atrophy (Matuszczak et al., 
2004). In contrast, XO inhibition during hindlimb unloading has been found to offer 
significant muscle sparing effects (Derbre et al., 2012). Altogether, the evidence 
implicates XO as having a regulatory role in the decline of contractile function 
associated with disuse, but it is still unclear whether or not XO promotes disuse atrophy. 
Two Nox isoforms are expressed in skeletal muscle fibers, Nox2 (Semprun-
Prieto et al., 2011; Lawler et al., 2014) and Nox4 (Sun et al., 2011). The Nox2 isoform 
is a plasma membrane associated multi-subunit complex that is capable of actively 
producing superoxide when cytosolic subunits bind to the membrane-bound subunits. 
Sustained activation of Nox, in particular Nox2, has been associated with skeletal 
muscle atrophy in vitro and in vivo (Semprun-Prieto et al., 2011; Abrigo et al., 2016). 
Our group recently reported that 54 hours of hindlimb unloading was associated with 
increased sarcolemmal localization of two Nox2 subunits, gp91phox and p47phox 
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(Lawler et al., 2014). Moreover, oxidative stress in response to mechanical ventilation 
has been linked to contractile dysfunction and fiber atrophy, both of which were 
attenuated by the administration of a Nox inhibitor (McClung et al., 2009). The limited 
evidence indicates that disuse-induced oxidative stress is partially the result of Nox 
activation. Links between Nox2 and mitochondrial ROS are currently unknown in disuse 
atrophy. 
2.4.3 Mechanistic Links Between Oxidative Stress and Disuse-Induced Atrophy  
Oxidative stress has been linked to the manipulation and slowing of the rate of 
muscle protein synthesis. Accumulating evidence from in vitro experiments suggest that 
elevated ROS concentrations interfere with the phosphorylation of Akt/mTORC1 
signaling and, in effect, limit translational efficiency (O'Loghlen et al., 2006; Shenton et 
al., 2006; Zhang et al., 2009; Tan et al., 2015). As previously mentioned, activation of 
Akt is suggested to be a transition point between hypertrophy and atrophy. Decreased 
Akt phosphorylation often results in lower rates of protein synthesis and increased 
degradation, which lead to atrophy. Recent in vivo investigations, have found that the 
disuse-associated increase in mitochondrial derived oxidants led to reductions in Akt 
activity (Talbert et al., 2013b; Hudson et al., 2015). For instance, elevated ROS in the 
immobilized soleus led to significant reductions in phosphorylation of Akt and mTORC1 
(Talbert et al., 2013b). Moreover, oxidative stress-associated inhibition of Akt, 
mTORC1, PRAS40, and 4E-BP1 were observed recently following mechanical 
ventilation (Hudson et al., 2015). These findings indicate that disuse-induced oxidative 
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stress reduces protein synthesis by inhibiting Akt/mTORC1 signaling and limiting 
translation.  
A growing body of evidence suggests that oxidative stress contributes to elevated 
rates of skeletal muscle proteolysis and atrophy through various routes. For instance, 
alterations in ROS production and signaling can regulate transcription factors and 
eventual gene expression of critical components of the UPP (Talbert et al., 2013b; 
Lawler et al., 2014). For example, disuse-associated oxidative stress has been shown to 
lead to increased dephosphorylation of cytoplasmic FoxO3a, which is suggestive of 
elevated nuclear FoxO3a content and activity (Lawler et al., 2014). Moreover, increased 
ROS due to hindlimb immobilization has been shown to significantly increase 
expression of FoxO3a target genes: MuRF-1 and MAFbx/Atrogin-1 (Talbert et al., 
2013b). Furthermore, disuse-induced oxidative stress promotes increased activity of the 
20S proteasome (Betters et al., 2004).  
Elevations in ROS production during disuse have also been implicated in 
regulating the expression and activity of components of the autophagy-lysosomal 
degradation pathway. For instance, inhibition of mitochondrial-derived ROS during 
disuse reportedly prevents the rise in autophagic vesicle formation and cathepsin 
expression (Talbert et al., 2013b). Disuse-induced elevations in ROS production have 
also been linked to the activation of both calcium-mediated calpains and caspase-3 (Min 
et al., 2011; Talbert et al., 2013b). Additionally, elevated levels of disuse-induced ROS 
can promote proteolysis in muscle fibers by oxidizing proteins thereby enhancing their 
susceptibility to proteolytic degradation (Ikemoto et al., 2002; Smuder et al., 2010). For 
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example, antioxidant administration during hindlimb unloading effectively attenuates 
protein ubiquitination and fragmentation of myosin heavy chain proteins (Ikemoto et al., 
2002). Altogether, those data strongly suggest a significant role for oxidative stress in 
the regulation of disuse-induced proteolysis. 
 Possible links between disuse-associated ROS and NFκB, ATF4, p53, and 
several of the recently discovered atrogenes leave many unanswered questions in 
atrophy signaling. The limited data that is available points towards the likelihood that 
many of these transcription factors and atrogenes are altered in response to disuse-
associated ROS. For example, antioxidant treatment during mechanical ventilation has 
verified oxidative stress as an upstream activator of NFκB and linked to diaphragm 
muscle weakness (Smuder et al., 2012). Furthermore, ATF4 expression was highly 
responsive to hydrogen peroxide stimulation in C2C12 myotubes (Pierre et al., 2014). In 
mechanically unloaded skeletal muscles, increased content of p53 has been suggested to 
lead to disturbances in the oxidative balance of the myofiber (Siu & Alway, 2005). 
Elevated levels of ROS have also been shown to induce expression of NEDD4-1 in 
brains from patients with Alzheimer’s, Parkinson’s, and Huntington’s diseases and 
spinal cords from amyotrophic lateral sclerosis (ALS) patients (Kwak et al., 2012). 
Additionally, recent evidence indicates that anthocynin (delphinidin) treatment during 
hindlimb unloading suppressed the expression of genes associated with oxidative stress 
while concomitantly preventing the rise in Cbl-b expression (Murata et al., 2016). 
Accumulating evidence suggests that ROS exerts a strong influence on transcriptional 
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regulation during disuse atrophy, possibly beyond what is currently known. Refer to 
Figure 2.1 for our proposed model of ROS regulation of atrophy gene transcription. 
 
 
 
Figure 2.1. ROS regulation of transcription factors and expression of proteins involved in promoting the 
reduction of fiber size due to disuse. Based on published findings, we propose a list of transcription factors along 
with E3 ligases and growth arresting proteins known to directly promote atrophy or exert blunting effects on synthesis 
pathways, each of which is likely influenced by elevated myofiber ROS. This is a simplified figure illustrating ROS-
regulation of disuse fiber atrophy; refer to text for further discussion. Transcription factors listed do not necessarily 
correspond to the list of E3 ligases and growth arresting factors. 
 
 
Altogether, a growing body of evidence suggests that oxidative stress can impede 
the rate of protein synthesis and accelerate protein degradation in a variety of ways, 
resulting in skeletal muscle atrophy. However, several gaps in knowledge are evident 
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concerning ROS and disuse. Future studies should examine the specific mechanisms 
responsible for the rise in ROS production during disuse-induced skeletal muscle 
atrophy, as well as the notion of cross-talk among oxidant sources. In the ROS-induced 
ROS-release model described by Andreas Daiber (2010), activation of Nox and 
subsequent superoxide production could lead to depolarization of mitochondrial 
membrane ATP potassium channels. The reduction in mitochondrial membrane potential 
would then lead to increased mitochondrial-derived ROS, which could activate PKC. 
Active PKC has been shown to be capable of triggering Nox2 complex formation and 
activation. In this model, the initial ROS production from Nox2 signals for the 
augmentation and intensification of oxidative stress from the mitochondria (Daiber, 
2010). In addition, activation of Fn14 has been shown to promote ROS production by 
stimulating Nox2 activity in macrophages (Madrigal-Matute et al., 2015). Thus it is 
possible that Nox2 serves as an intermediate in an Fn14 – Nox2 – NFκB pathway. 
Clearly, there are many unanswered questions and continuing research efforts will be 
required to elucidate our understanding of both the locations and regulation of ROS 
production during disuse-induced skeletal muscle atrophy. 
2.5 Potential Role of Neuronal Nitric Oxide Synthase-mu During Disuse Atrophy 
Currently, we do not have a full understanding of the complexities involved in 
oxidant production during disuse-induced skeletal muscle atrophy. Skeletal muscle 
wasting that occurs during pathological conditions, such as sepsis and chronic heart 
failure, has been associated with an over-production of nitric oxide (•NO) (Adams et al., 
1997; Nin et al., 2004). However, upregulation of the inducible nitric oxide synthase 
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(iNOS), rather than the neuronal nitric oxide synthase isoform (nNOS), was cited as 
causal in cachectic muscle atrophy. 
However, during disuse-induced atrophy it is unclear whether excess •NO 
production, source, or localization accelerates the atrophic process. In a study by Suzuki 
et al. (2007), 14 days of hindlimb unloading was associated with a sarcoplasmic 
translocation of the mu (µ) – isoform of neuronal nitric oxide synthase (nNOSµ) from 
the sarcolemma-localized dystrophin glycoprotein complex (DGC), and this 
translocation correlated with elevated levels of sarcoplasmic •NO (Suzuki et al., 2007). 
Their group followed this experiment up with genetic and pharmacological nNOS 
inhibition studies that indicated translocation of nNOSµ activity during hindlimb 
unloading as a critical event promoting atrophy (Suzuki et al., 2007). Dystrophin 
remained attached to the DGC while dysferlin, a multifunctional protein involved in 
membrane repair, remained bound to nNOSµ. Inhibition of nNOS prevented activation 
of FoxO3a and ubiquitin ligases (Suzuki et al., 2007). Cytosolic levels of •NO were 
elevated as determined via EPR (electron paramagnetic resonance). We found that 
nNOSµ translocation is an early event in the mechanical unloading process, occurring 
within 3 days with the rat model (Lawler et al., 2014)  In addition, Vitadello et al. 
(2014a) also found untethering of nNOSµ from the sarcolemma and translocation of 
nNOSµ with hindlimb unloading, linked to downregulation of grp94 (Vitadello et al., 
2014b). Grp94 is an HSP90-like stress protein that chaperones protein folding (Marzec 
et al., 2012).  
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In contrast, Lomonosova et al. (2011) reported that L-arginine mitigated 
hindlimb unloading-induced reduction of nNOS, •NO, dystrophin, and HSP90 protein 
levels and mRNA transcripts gene expression. Heterogeneity in dystrophin sarcolemmal 
localization was found, suggesting disruption of the DGC. Furthermore, hindlimb 
unloading reduced levels of desmin (Lomonosova et al., 2011), a z-disc fiber protein that 
transmits loading to the DGC and surrounding extracellular matrix protein (e.g., laminin, 
collagen). Protein abundance was determined from serial frozen cross-sections, and thus 
assessed global levels, rather than site-specific changes. Efficacy of L-arginine may 
suggest a substrate limitation or de-coupling of nNOSµ. In addition, a different spin trap 
was used for EPR in the Lomonosova study compared with Suzuki et al.: diethyl-
dithiocarbamate (DETC) vs. N-methyl-D-glucamine-dithiocarbamate (MGD). Thus the 
global role of •NO and downstream nitrosative species remain uncertain in unloading 
induced atrophy. However, we propose that (1) disruption of the DGC and membrane 
environment and untethering of nNOSµ from the sarcolemma, (2) subcellular location of 
nNOS and downstream effects on FoxO3a-ubiquitin ligase signaling, (3) substrate 
availability, (4) the role of other NOS isoforms, and (5) local •NO bioavailability may be 
more important than global •NO levels in regulating muscle fiber atrophy with 
mechanical unloading. However, additional research is crucial to unraveling these 
mysteries. 
Interestingly, evidence indicates NOS and •NO are involved in the regulation of 
the type I MHC isoform (Sellman et al., 2006; Suwa et al., 2015). For instance, a recent 
report found that with 8 weeks of NOS inhibition there was a significant decrease in the 
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percentage of type I fibers and concomitant increase in the percentage of type IIa fibers 
in the soleus muscle (Suwa et al., 2015). Since disuse leads to a shift in fiber type from 
type I to type IIa, those data point towards the notion that a reduction in myofiber •NO 
may be a critical event promoting the shift.   
It is proposed that in healthy muscle sarcolemma-localized nNOSµ is required 
for myofiber mechanotransduction. For example, muscle fiber hypertrophy with 
mechanical overloading was dependent upon intact sarcolemmal nNOSµ and NADPH 
oxidase 4 (Nox4) (Ito et al., 2013). Genetic ablation or inhibition of nNOSµ early in the 
overloading process attenuated muscle hypertrophy by over 50% (Ito et al., 2013). In 
support of these findings, the reduction in sarcolemma nNOSµ that occurs with 
unloading leaves the muscle fiber susceptible to sarcolemma lysis by neutorphils upon 
reloading (Nguyen & Tidball, 2003), thus slowing recovery. Whereas, mice expressing a 
muscle-specific nNOS transgene were significantly protected from sarcolemma damage 
and injury in response to reloading (Nguyen & Tidball, 2003). Clearly, nNOSµ plays a 
vital role as a load sensitive molecule in skeletal muscle. Translocation of nNOSµ has 
been reported to occur in response to various forms of disuse: hindlimb unloading 
(Tidball et al., 1998; Suzuki et al., 2007; Lawler et al., 2014), spaceflight (Sandona et 
al., 2012), denervation (Suzuki et al., 2007), bed rest (Rudnick et al., 2004), and 
intensive care-associated critical illness myopathy (Llano-Diez et al., 2012). While some 
have observed disuse-induced alterations in nNOSµ synthesis and/or degradation, the 
mislocalization of nNOSµ in postural muscles is a common event associated with 
atrophy. Suzuki et al. (2007) observed a causal link between nNOSµ untethering and 
 26 
 
proteolytic FoxO3a activation during hindlimb unloading. Our group demonstrated that 
administration of a superoxide dismutase (SOD) / catalase mimetic (EUK134) reduced 
the extent of nNOSµ untethering from the sarcolemma and translocation to the 
sarcoplasm following 54 hours of hindlimb unloading (Lawler et al., 2014). This effect 
attenuated the activation of FoxO3a, subsequent atrophy and shift in fiber type in the 
soleus muscle (Lawler et al., 2014). In support of these observations, mice treated with 
curcumin, which contains antioxidant and anti-inflammatory properties, mitigated 
nNOSµ translocation and atrophy (Vitadello et al., 2014a). Those data suggest that 
disuse-induced translocation of nNOSµ is due in part to a rise in oxidative stress. 
Much remains to be learned concerning the many roles of nNOSµ during 
mechanical unloading. For example, further examination is needed to elucidate whether 
translocated nNOSµ leads to elevated localized •NO within the sarcoplasm of the fibers 
and which signaling pathways are affected. Does nitrosylation of glutathione play a role 
in dephosphorylation of FoxO3a?  What are the mechanisms of substrate limitation? 
What are the mechanisms underlying redox regulation of nNOSµ during unloading? A 
causal link between nNOSµ translocation is directly associated with depressed protein 
synthesis is also of interest. In addition, identifying the molecular mechanisms guiding 
nNOSµ untethering from dystrophin and alpha-syntrophin in the DGC are of significant 
concern. In addition, are the effects of nNOSµ translocation fiber type-dependent? Does 
nNOSµ translocation trigger fiber-type switch from slow to fast-twitch with unloading?  
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2.6 Conclusions 
In summary, disuse-induced skeletal muscle atrophy is due in part to the stressful 
myofiber environment caused by elevations in ROS. Oxidative stress is implicated as a 
mechanism for blunted rates of muscle protein synthesis and increased proteolysis 
(summarized in Figure 2.2). Various myofiber oxidant sources participate in the 
production of ROS and are potentially involved in a ROS-induced ROS-release feedback 
mechanism. In addition, future studies are needed to determine the specific upstream 
signaling events that trigger the disuse-induced ROS production from each oxidant 
source. While the data remains unclear concerning •NO production during disuse, there 
is a better understanding of the link between atrophying muscle and nNOSµ 
translocation. However, future studies are needed to elucidate the connections between 
oxidative stress, nNOSµ translocation, and the affected atrophic signaling cascades. 
 
 
 
 
 28 
 
 
Figure 2.2. Critical signaling pathways controlling muscle fiber size during disuse-induced atrophy and the 
regulatory schemes exerted by ROS. The combination of reactive oxygen species (ROS) derived from mitochondria, 
NADPH oxidase isoform 2 (Nox2), and xanthine oxidase (XO) results in an increased ROS concentration in 
myofibers during periods of disuse. Elevated ROS can blunt Akt-mTORC1 protein synthesis signaling, induce 
dislocation of nNOSµ from the DGC towards the sarcoplasm, enhance dephosphorylation of FoxO1/3a, and promote 
NFkB signaling. In addition, ROS from Nox2 and/or mitochondria may promote a ROS-induced ROS-release 
amplification scheme (as shown by the dashed red-line with arrowheads). ROS regulatory functions are shown with 
red lines. Dashed lines indicate hypotheses concerning signaling events made by the authors based on published 
research findings. This is a simplified figure illustrating ROS-regulation of disuse fiber atrophy; refer to text for brief 
discussions on alternative pro-degradation routes (e.g. calpains, caspase-3, autophagy-lysosomal). 
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CHAPTER III  
AT1 RECEPTOR BLOCKADE ATTENUATES HINDLIMB UNLOADING-
INDUCED MODIFICATIONS OF NOX2, NNOS, AND FOXO3A SIGNALING IN 
SKELETAL MUSCLE 
 
3.1 Introduction 
Maintenance of skeletal muscle mass and function is critical for our overall 
health and quality of life. The result of prolonged periods of disuse, such as forced 
bedrest, limb casting, and spaceflight, is a loss of skeletal muscle mass. While there are 
various forms of disuse, the underlying cellular mechanisms share some similarities. 
Skeletal muscle atrophy is primarily due to an imbalance in muscle protein turnover, 
characterized by a reduction in protein synthesis and an upregulation in protein 
degradation (Schiaffino et al., 2013). Understanding the various pathways involved in 
the blunted synthesis and elevated degradation rates leading to disuse-induced skeletal 
muscle atrophy is imperative to making progress towards therapeutic interventions that 
aim to mitigate, delay, or even prevent atrophy. 
 The protein synthesis vs. degradation imbalance is due in part to blunting of Akt / 
mTORC1 signaling and increased activity of the various proteolytic pathways 
(Schiaffino et al., 2013; Egerman & Glass, 2014). The primary degradation pathways 
involved in disuse atrophy are the ubiquitin proteasome pathway (UPP), the calcium-
dependent caspase-3 and calpains, and the autophagy-lysosomal pathway (Powers et al., 
2007; Schiaffino et al., 2013). A critical signaling event during disuse atrophy is the 
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activation of forkhead members of the class O (FoxO) transcription factors (i.e., 
FoxO1/3a). FoxO1/3a are implicated in the regulation of myofiber size through 
transcriptional regulation of atrogenes such as ubiquitin E3 ligases, muscle-specific 
RING finger protein 1 (MuRF1) and muscle atrophy F-box (MAFbx) / atrogin-1 (Bodine 
et al., 2001; Schiaffino et al., 2013). Along with FoxO1/3a, recent evidence indicates 
that ATF4 and p53 function as transcription factors during short-term disuse, promoting 
the expression of growth-arresting proteins ((Fox et al., 2014). The extent to which the 
various pathways are involved in disuse atrophy depends the type of disuse, length of 
disuse, and fiber composition of the muscle.  
 Prolonged periods of disuse are associated with increased production of reactive 
oxygen species (ROS) in skeletal muscle fibers (Kondo et al., 1993; Lawler et al., 2003). 
The disuse-induced elevation in oxidative stress is theorized to be a trigger of atrophic 
signaling. Three oxidant sources linked to disuse atrophy include ROS from the electron 
transport chain in mitochondria (Min et al., 2011; Talbert et al., 2013b), xanthine 
oxidase (XO) (Matuszczak et al., 2004; Derbre et al., 2012), and NADPH oxidase (Nox) 
(Lawler et al., 2014). While mitochondria are likely the primary source of ROS during 
disuse (Min et al., 2011), the contribution of XO and Nox cannot be overlooked. 
Skeletal muscle cells are known to have two Nox isoforms: Nox2 (Semprun-Prieto et al., 
2011; Lawler et al., 2014) and Nox4 (Sun et al., 2011). Nox2 is a multi-subunit complex 
that consists of two membrane-bound subunits (gp91phox and p22phox) and four 
cytosolic subunits (p40phox, p47phox, p67phox, and Rac-1). Nox2 complexes become 
active when the cytosolic subunits join the sarcolemmal subunits and convert oxygen to 
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the superoxide radical, as depicted in Figure 3.1. We recently reported that 54 hours of 
hindlimb unloading was associated with increased sarcolemmal content of two Nox2 
subunits, gp91phox and p47phox (Lawler et al., 2014). In addition, Nox inhibition 
attenuates disuse-induced contractile dysfunction and fiber atrophy in the rodent 
mechanical ventilation model (McClung et al., 2009). Activation of Nox2 appears to be 
dependent upon Rac-1 activation and protein kinase C (PKC) activation of p47phox 
(Balakumar & Jagadeesh, 2014). Upstream signaling events include angiotensin II 
(AngII) ligand-binding of the AngII type 1 receptor (AT1R) which leads to 
phosphorylation of PKC and subsequent Nox2 activity (Balakumar & Jagadeesh, 2014). 
Furthermore, exposure of skeletal muscle cells to elevated levels of AngII is known to 
result in atrophy (Semprun-Prieto et al., 2011; Kadoguchi et al., 2015). Moreover, in the 
rat model of hindlimb unloading, plasma AngII is significantly increased following 7 
days of disuse (Chung et al., 2012).  
 
 
 
Figure 3.1. Illustration of inactive versus active Nox2 complex formation. Active conformation requires cytosolic 
components to join the membrane bound subunits. 
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Our previous findings have also established a link between the disuse-induced 
increase in ROS production and the translocation of sarcolemma-localized neuronal 
nitric oxide synthase (nNOS) to the sarcoplasm (Lawler et al., 2014). Translocation of 
nNOS occurs in a variety of disuse models, and the rise in sarcoplasmic nNOS content 
has been implicated in the dephosphorylation / activation of FoxO3a (Suzuki et al., 
2007; Llano-Diez et al., 2012; Sandona et al., 2012; Lawler et al., 2014), as illustrated in 
Figure 3.2. We have postulated that elevated Nox2-derived ROS occuring during disuse 
is critical to the nNOS dislocation and subsequent activation of FoxO3a and, therefore, 
the resulting atrophy. 
 
 
 
Figure 3.2. Illustration of the consequence of mechanical unloading-induced rise in ROS and subsequent nNOS 
untethering from the sarcolemma localized dystrophin glycoprotein complex (DGC). 
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In the present study, we evaluated the effects of AT1R blockade in hindlimb 
unloaded rats on soleus muscle morphology, fiber type, oxidative stress, and markers of 
skeletal muscle atrophy. We hypothesized that administration of the AT1R antagonist, 
losartan, would mitigate the negative effects associated with mechanical unloading, such 
as reduction in muscle fiber cross-sectional area, slow-to-fast fiber type shift, elevated 
ROS production, accumulation and activation of Nox2, nNOS translocation, and nuclear 
localization of pro-atrophy transcription factors (summarized in Figure 3.3).  
 
 
 
Figure 3.3. Proposed model of the influence of AT1R activation during hindlimb unloading-induced atrophy. 
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3.2 Materials and Methods 
3.2.1 Animals 
All animal procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Texas A&M University. Young adult (4-5 months) Fischer-344 
(F344) rats were subjected to skeletal muscle disuse via hindlimb unloading. Animals 
were housed and cared for in accordance with the National Institutes of Health policy 
(NIH: DHEW publication no. 85-23, revised 1985). Rat chow (4% fat) and water were 
provided ad libitum, and the animals were maintained in a temperature-controlled room 
(23 ± 2°C) with a 12:12 hour light-dark cycle. Rats are valuable models for the 
examination of skeletal muscle wasting that occurs during disuse and unloading in 
humans, with disuse-induced responses such as changes in muscle fiber cross-sectional 
area, weakness and fiber type shifting from slow to fast common to both the rat and 
human responses. 
3.2.2 Hindlimb Unloading 
Systemic physiological effects of microgravity and bed rest are accurately 
replicated in the ground-based hindlimb unloading model. An adaptation of the rodent 
tail-suspension hindlimb unloading model (Globus & Morey-Holton, 2016) was utilized 
to induce mechanical unloading. Rats were anesthetized with an intraperitoneal (i.p.) 
injection of a ketamine (75 mg/kg) / xylazine (10 mg/kg) cocktail solution to induce 
unconsciousness, dampened sensations, and muscle relaxation allowing research 
personnel to harness the tail. Tail harnesses were then connected to a cross-wire that 
spanned across the top of the cage. The hindlimbs of the rats were lifted so that their 
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hindfeet were approximately 1 mm off of the cage floor. Hindlimbs of the rats remained 
unloaded for a total of 7 days. At the end of the 7-day period, rats were sacrificed. Rats 
were euthanized with 120 mg/kg i.p. sodium pentobarbital (Euthanasia III Solution).  
3.2.3 Experimental Design 
A hindlimb unloading duration was chosen to target the early stages of skeletal 
muscle remodeling during disuse. Markers of atrophy and oxidative stress have been 
observed to peak or be near a peak state at the 7-day time point during disuse (Dupont et 
al., 2011). We used a United States Food and Drug Administration (FDA)-approved 
angiotensin II type 1 receptor blocker, losartan, as an intervention to target the potential 
upstream trigger of oxidative stress during disuse. Adult F344 rats were divided into four 
groups (n = 7 / group): loaded controls (CON), 7 days of hindlimb unloading (HU), 7 
days of HU + 40 mg/kg/day i.p. of losartan (HUL), and loaded controls + losartan 
(CONL). Please refer to the Appendix for justification of the losartan dosage used in 
this study. CON and HU rats received daily i.p. injections of similar volumes of 
physiological saline. Administration of losartan or saline began 24 hours prior to 
hindlimb unloading and continued throughout the 7-day unloading period (8 days total). 
Sample size calculations were based on soleus muscle fiber cross-sectional area, which 
has the lowest mean percentage difference among our results in preliminary studies. 
3.2.4 Skeletal Muscle Tissue Preparation 
The soleus muscle was chosen as a model of skeletal muscle response to 
mechanical unloading disuse. As a postural muscle with a high percentage of Type I 
(slow twitch) fibers, the soleus is susceptible to rapid atrophy and remodeling when 
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exposed to mechanical unloading (Ohira et al., 1992). Rats were euthanized with 120 
mg/kg of pentobarbital sodium salt (Euthanasia III Solution) by way of an i.p. injection. 
The soleus muscles were extracted, trimmed of excess tissue, rinsed with phosphate-
buffered saline (PBS) solution and laid longitudinally on a polyurethane mount of tissue 
freezing medium before being frozen in liquid nitrogen-cooled isopentane (2-
Methylbutane). Samples were subsequently stored at -80°C until needed for the 
following experimental techniques or assays. 
3.2.5 Subcellular Fractionation 
Soleus muscles were minced, weighed, and washed with cold PBS prior to 
homogenization. Subcellular fractionation was performed using adaptations of the 
methods described by (Brenman et al., 1995) and (Dimauro et al., 2012) (summarized in 
Figure 3.4A). Soleus samples were homogenized in lysis Buffer A (10:1 w/v) containing 
the following: 25 mM Tris-HCL, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
and protease inhibitor cocktail. Muscles were homogenized using a motorized ground 
glass-on-ground glass mortar and pestle at 4°C. Nuclei and debris were pelleted by 
centrifugation at 1,000xg for 10 minutes. The resulting supernatant was then centrifuged 
at 20,000xg. The resulting supernatant was the cytoplasmic fraction while the remaining 
pellet was re-suspended in Buffer A and deemed the crude-microsomal/membrane 
fraction.  
The nuclear fraction was isolated as described by Dimauro et al. (2012) with 
minor modifications. Nuclei and debris pelleted following centrifugation at 1,000xg (as 
noted in the previous paragraph) was re-suspended in Buffer B (6:1 w/v) which 
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contained 250 mM sucrose, 50 mM Tris-HCL pH 7.4, 5 mM MgCl2, and protease 
inhibitor cocktail, vortexed and then centrifuged at 500xg for 15 minutes. The resulting 
supernatant was discarded and the pellet was re-suspended in Buffer B, vortexed and 
then centrifuged at 1,000xg for 15 minutes. Once again, the supernatant was discarded 
and the pellet was re-suspended in Buffer C (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.5 
M NaCl, 0.2 mM EDTA, 20% glycerol, 1% Triton-X-100, protease inhibitor cocktail). 
This fraction incubated on ice for 30 minutes and was intermittently vortexed. Next, the 
fraction was centrifuged at 9,000xg for 30 minutes, and the resulting supernatant was 
deemed the nuclear fraction. 
Protein concentrations were determined using the Bradford protein assay, 
following the manufacturer’s instructions (Bio-Rad, cat # 500-0006). Tissue extracts 
were subsequently aliquoted and stored at -80°C until western blot analysis. Validation 
of each subcellular fraction was assessed by western blotting (Figure 3.4B) for GAPDH 
(cytoplasmic) (1:10,000, EMD Millipore, cat # MAB374), Na+/K+ ATPase α-1 (crude 
membrane) (1:1,000, EMD Millipore, cat # 05-369), and Histone H3 (nuclear) (1:1,000, 
Cell Signaling Technology, 9715). 
3.2.6 Western Blotting 
Soleus muscle extracts (20 µg or 30 µg) along with sample buffer were loaded 
into wells of 8% or 10% SDS-PAGE gels. Electrophoresis was conducted at 120 V for 
~75 min. Gels were then transferred at 100 V for ~60 min onto a nitrocellulose  
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Figure 3.4. Validation of subcellular fractionation preparation. Soleus muscle lysates were used to isolate the 
membrane, cytosolic, and nuclear subcellular fractions. A, flow chart of the fractionation protocol. B, detection of the 
various proteins. Western blot detection of Na+/K+ ATPase, GAPDH, and Histone H3 were used to confirm the 
membrane, cytosolic, and nuclear fractions, respectively. C, the PVDF membrane stained with Ponceau S Red stain 
following the blotting procedures. Each lane contained 30µg of protein: cyotosolic (C) fraction in lane 1, Membrane 
(M) fraction in lane 2, and nuclear (N) fraction in lane 3.  
 
 
membrane (Bio-Rad, cat # 162-0112). Membranes were blocked in a non-fat milk buffer 
(5% non-fat milk in TBS) for 1 h. Following blocking, membranes incubated overnight 
(4°C) in blocking buffer with the appropriate primary antibody: anti-nNOS (1:750, Life 
Technologies, cat # 61-700), anti-gp91phox (1:1000, BD Biosciences, cat # 611415), 
anti-p67phox (1:2500, BD Biosciences, cat # 610913), anti-p47phox (1:750, BD  
Biosciences, cat # 610355), anti-Rac1 (1:500, EMD Millipore, cat # 07-1464), anti-
FoxO3a (1:750, Cell Signaling Technology, cat # 12829), and anti-p53 (1:750, Cell 
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Signaling Technology, cat # 2527). Membranes were subsequently washed in tris 
buffered saline (TBS) with 0.1% Tween-20 (TBS-T) (3 x 5 min) and then incubated at 
room temperature for 1 h in blocking buffer containing the appropriate HRP-conjugated 
secondary antibodies (Santa Cruz Biotechnology, cat # sc-2004 or sc-2005). After TBS-
T washes, proteins were visualized by Super Signal West Dura Extended Duration 
Substrate (Thermo Scientific, cat # 34076) enhanced chemiluminescence detection and 
developed with the Fuji LAS-3000 Luminescent Image Analyzer (FujiFilm Medical 
Systems). Quantification was performed using NIH ImageJ software. Ponceau-S staining 
(cytoplasmic: band ~38 kDa mark (GAPDH); crude membrane: band ~42 kDa mark 
(actin); nuclear: band ~42 kDa mark (actin)) was used as a loading control. 
3.2.7 Histological Analysis 
Soleus muscles were embedded in tissue freezing medium and subsequently 
frozen. Muscles were cut in 10 µm sections from the midbelly of the muscle using a 
cryostat (Thermo Scientific, Shandon Cryotome FSE) and allowed to air-dry for 30 
minutes. Hematoxylin and eosin (H&E) stains were used to assess tissue morphology 
and performed as previously described (Lawler et al., 2014).  
Muscle sections were also stained with wheat germ agglutinin (WGA) Alexa 
Fluor 555 conjugate (WGA-Alexa 555, 1:40, Life Technologies, cat # W32464) in order 
to visualize the sarcolemma and connective tissue. Sections were co-stained with a DAPI 
solution (1:500, Life Technologies, cat # D1306) for 5 min according to the 
manufacturer’s guidelines. Slides were air-dried prior to coverslip mounting with 
Prolong Gold anti-fade medium (Life Technologies, Grand Island, NY). 
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NADPH-diaphorase histochemical analysis was used to examine the presence 
and localization of active nNOS. This assay was performed as previously described 
(Vitadello et al., 2014b) with minor modifications. Ten µm soleus muscle sections were 
fixed for 20 min with 2% paraformaldehyde followed by a PBS wash. Sections were 
then incubated in a buffer containing 50 mM Tris-HCl pH 8.00, 0.2% Triton-X-100, 0.5 
mM nitrotetrazolium blue chloride, and 1 mM β-NADPH for 2 h at 37°C. The enzymatic 
reaction was stopped by briefly rinsing the slides with distilled water and then allowed to 
air-dry. Coverslips were mounted onto the samples with permanent mounting medium 
(Vectamount, Vector Laboratories, cat # H-5000). 
Stained sections were visualized and photographed with a Zeiss Axioplot upright 
microscope and Zeiss Axiocam HRc color camera (Carl Zeiss Microimaging, 
Thornwood, NY). Images from WGA stained cross-sections (n = 5 - 6 / group) were 
quantified using NIH ImageJ to determine the percentage of area positively stained by 
WGA, as well as the integrated density of the WGA stained portions. NADPH-
diaphorase stained samples (n = 5 - 6 / group) were quantified by using NIH ImageJ to 
obtain the cross-sectional circumference (CSC) and determining the percentage of the 
sarcolemma that stained positively for NADPH-diaphorase.  
3.2.8 Immunofluorescence 
To examine protein localization, soleus muscle cross-sections obtained from the 
midbelly were serially sectioned at 10 µm thick in a cryostat at -15°C and placed onto 
microscope slides. Samples were fixed in either acetone (myosin heavy chain 
immunofluorescence) at -20°C for 10 min or in 2% paraformaldehyde followed by a 20 
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min incubation in citrate buffer at 92°C (nNOS and FoxO3a immunofluorescence). 
Following fixation, sections were washed in PBS with 0.1% Tween20 (PBS-T). Sections 
were blocked in a 10% normal goat serum (ThermoFisher Scientific, cat # 50062Z) for 
15 min. After blocking, sections incubated in blocking buffer containing specific 
primary antibodies: dystrophin (1:100, Santa Cruz Biotechnology cat # sc-15376), slow 
skeletal myosin heavy chain (1:250, Abcam, cat # ab11083), fast skeletal myosin heavy 
chain (1:250, Abcam, cat # ab51263), nNOS (1:100, Cayman Chemical, cat # 160870), 
FOXO3a (1:50, Sigma-Aldrich, cat # SAB3500508), and Beta-Sarcoglycan (1:200, 
Abcam, cat # ab55683) for 1 hour in an enclosed chamber at room temperature. After 
three 5 min washes in PBS, sections were incubated in the appropriate secondary 
antibody with a fluorophore attached (e.g., goat anti-rabbit Alexa Fluor 488, goat anti-
mouse Alexa Fluor 594) (1:200) for 30 min at room temperature. Sections were 
subsequently washed twice in PBS-T and once in PBS. Some instances required DAPI 
staining, which involved 5 min incubation followed by PBS washes. Slides were allowed 
to air-dry prior to mounting with Prolong Gold anti-fade medium (Life Technologies, 
Grand Island, NY). Images were captured on a Zeiss Axioplot upright microscope and 
Zeiss Axiocam HRc color camera.  
Muscle fiber CSA was determined on β-sarcoglycan- and dystrophin-stained 
muscle cross sections by employing the semi-automatic muscle analysis using 
segmentation of histology (SMASH) MATLAB-based program (Smith & Barton, 2014). 
A range of 200-250 fibers per muscle were quantified to obtain an average CSA from 
each sample (n = 7 / group). Quantification of the percentage of FoxO3a positive 
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myonuclei was accomplished by triple staining soleus sections with anti-FoxO3a, anti-β-
Sarcoglycan, and DAPI to determine the co-localization of FoxO3a with myonuclei. A 
minimum of 300 myonuclei were counted per muscle sample (n = 4 / group) to obtain 
the percentage of FoxO3a positive myonuclei. 
3.2.9 Oxidative Stress Marker 
ROS generation was determined via a dihydroethidium (DHE) fluorescence 
protocol on soleus cross-sections. DHE is oxidized by superoxide to produce a 
fluorescent ethidium. Soleus muscle sections (10 µm) were air-dried and re-hydrated 
with PBS. Sections then incubated with 5 µmol DHE (Life Technologies, cat # D1168) 
in a dark, humidified chamber for 30 min at 37°C. Muscle sections were washed with 
PBS, air-dried and mounted with ProLong Gold Anti-fade mounting medium. 
Immediately after mounting the coverslips, images taken at 10x magnification were 
obtained using the Zeiss Axioplot microscope and HRc color camera. Ethidium-positive 
nuclei were quantified using particle analysis functions on NIH ImageJ. Four images 
taken at 10x magnification were quantified per sample (n = 6).   
NADPH-dependent superoxide production was assessed with the lucigenin 
chemiluminescent assay (Heymes et al., 2003; Whitehead et al., 2010). Soleus muscle 
tissues were pooled together (n = 3 per pool) and homogenized in ice-cold buffer 
containing 25 mM Tris-HCL, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, and a 
protease inhibitor cocktail. Protein concentrations of the total homogenate were 
determined by Bradford assay. Experiments were performed on a microplate 
luminometer (BioTek Synergy 4 Microplate Reader; 37°C) using 100 µg protein per 
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well, NADPH (300 µM) and lucigenin (10 µM). In order to confirm that the signal was 
due to superoxide production, a superoxide dismutase mimetic (EUK-134, 50µM, 
Cayman Chemical, cat # 10006329) was used to scavenge superoxide. In addition, 
pharmacological inhibitors were used to confirm that the activity was primarily due to 
NADPH oxidase: the non-specific NADPH oxidase inhibitor diphenyleneiodonium 
(DPI, 10 µM, Sigma-Aldrich, cat # D2926) and the selective (Csanyi et al., 2011) Nox2 
inhibitor gp91ds-tat (5 µM, BioSynthesis, Inc., Lewisville, TX). 
3.2.10 Statistical Design 
All data reported here are as mean ± SEM. Statistical analysis was performed 
using GraphPad 6 software (GraphPad Software, Inc. San Diego, CA). One-way 
ANOVA was used to identify differences among CON, HU, HUL, and CONL. Tukey’s 
post-hoc analysis was utilized when necessary. Significance level for all tests was set at 
p < 0.05. 
3.3 Results 
3.3.1 Hindlimb Unloading-Induced Alterations in Soleus Muscle Morphology, but not 
Soleus Mass, are Mitigated by AT1R Blockade. 
We tested the hypothesis that AT1R blockade would ameliorate the hindlimb 
unloading-induced morphological alterations in soleus muscles. A previous study found 
that AT1R blockade offers protection against limb-stapling-induced atrophy in 
sarcopenic mice (Burks et al., 2011); however, we currently do not know if AT1R 
blockade is effective at preventing unloading-induced fiber atrophy in young, adult rats. 
In the current study, we found that seven days of hindlimb unloading resulted in a 
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significant drop in body weight compared to the control group (287.1 g vs 342.1 g; p = 
0.003) (Table 3.1). Administration of losartan during HU did not offer significant 
protection against the HU-induced reduction in body weight (299 g vs 287.1 g; p = 
0.826). In addition, soleus muscles from HU rats were significantly smaller than those 
from controls (103 mg vs 123.1 mg; p = 0.001) (Table 3.1). Soleus muscles from HUL 
rats were not significantly protected from the HU-induced drop in muscle weight (106.8 
mg vs 103 mg; p = 0.8687). Ambulatory control rats that received losartan (CONL) did 
not differ from CON rats in body weight (p = 0.999) or soleus weight (p = 0.9043). 
 
 
 
 
Table 3.1. Effect of AT1R blockade on body weight, soleus muscle weight, and soleus muscle weight / body 
weight in control and hindlimb unloaded rats. Body weight is expressed in grams (g). Soleus weight is expressed in 
milligrams (mg). Data are expressed as mean ± SEM. Values sharing the same letter are not significantly different (p < 
0.05): a indicates different from CON; d indicates different from CONL. 
 
 
Quantification of the average cross-sectional area (CSA) of the soleus muscles 
indicates that unloading resulted in a significant reduction of 34% in myofiber CSA 
compared to ambulatory controls (3469 µm2 vs 2291 µm2; p < 0.0001). Losartan 
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administration offered significant protection against unloading-associated reduction in 
fiber CSA (2996 µm2 vs 2291 µm2; p = 0.001), but still remained significantly smaller 
than CON (p = 0.0328). The majority of fibers in HU muscles were in the 1000 - 3000 
µm2 range (84.5%), whereas 83.8% of the CON fibers were found in the 2000 – 4500 
µm2 range. Fibers from the HUL muscles were predominately in the 1000 – 4500 µm2 
range (85.9%), exhibiting a wider range of fiber CSA than the HU muscles (Figure 
3.5A). Interestingly, we found that losartan reduced unloading-induced muscle fiber 
atrophy primarily in Type I fibers (3436 µm2 v. 2257 µm2; p = 0.0002) but did not offer 
protection in Type II fibers (2203 µm2 v. 1931 µm2; p = 0.4668) (Figure 3.5B). Fiber 
CSA from CONL rats did not differ from CON rats in fiber CSA. 
Additionally, we assessed whether the mechanical unloading-induced shift of 
soleus muscle fiber type from slow to fast (i.e., Type I to Type II) was impacted by 
AT1R blockade. Representative immunofluorescent fiber-type specific stains are shown 
in Figure 3.6A. As expected, unloading resulted in a significant reduction in the 
percentage of Type I fibers compared to CON (75.41% vs 88.34%; p < 0.0001) (Figure 
3.6B), concomitant with a significant increase in the percentage of Type II fibers 
(24.59% vs 11.66%; p < 0.0001) (Figure 3.6C). These effects were mitigated with 
losartan administration; however, HUL soleus muscle fiber type composition still 
remained significantly different from CON, with a 6.46% difference (p = 0.0015) 
(Figure 3.6B & C). Soleus muscle fiber type composition did not differ between CON 
and CONL rats. 
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Figure 3.5. AT1R blockade mitigates soleus muscle fiber atrophy for Type I but not Type II fibers due to one 
week of hindlimb unloading. A, Distribution of muscle fibers according to fiber cross-sectional area (CSA) for 
controls (CON), hindlimb unloaded (HU), hindlimb unloaded + losartan (HUL), and control + losartan (CONL) (n = 7 
/ group). B, Average CSA for each group. C, Muscle fiber CSA by fiber type. Values are means ± SEM. Values 
sharing the same letter are not significantly different (p < 0.05): a indicates different from CON; c indicates different 
from HUL; d indicates different from CONL. 
 
 
Through the use of wheat germ agglutinin (WGA) to visualize connective tissue 
in soleus muscle cross-sections, we found a significant 42.2% increase in extra-myofiber 
tissue area due to hindlimb unloading (p < 0.0001) (Figure 3.7A & B). Furthermore, HU 
led to a significant increase of 23% in WGA fluorescent intensity (p < 0.0001) (Figure 
3.7C), indicative of an elevated concentration of connective tissue. Losartan treatment 
resulted in an anti-fibrotic effect, preventing the hindlimb unloading-induced 
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Figure 3.6. Hindlimb unloading-induced shift in fiber type is reduced in losartan treated rats. A (top row), 
representative immunofluorescence images of soleus muscles stained for type II muscle fibers (orange) and dystrophin 
(green); (bottom row), images of soleus muscles stained for type II muscle fibers (red) and type I muscle fibers 
(green). Scale bar = 100 µm. B, percentage of soleus muscle fibers that are type I fibers. C, percentage of muscle 
fibers that are type II fibers. Values are means ± SEM. Values sharing the same letter are not significantly different (p 
< 0.05): a indicates different from CON; c indicates different from HUL; d indicates different from CONL. 
 
 
 
 
accumulation of connective tissue in both area (p < 0.0001) (Figure 3.7B) and intensity 
(p = 0.0024) (Figure 3.7C). Once again, build-up of extra-myocyte components were 
not significantly different between CON and CONL groups. 
 3.3.2 Increased ROS Production During Hindlimb Unloading is Partially Prevented by 
Losartan Treatment 
In the next set of experiments, we tested the hypothesis that hindlimb unloading- 
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Figure 3.7. Mechanical unloading leads to an increase in connective tissue. A (top row), representative images of 
hematoxylin & eosin (H&E) stained soleus muscles; (bottom row), representative images of muscles stained for wheat 
germ agglutinin (WGA) and DAPI. Scale bar = 100 µm. B, quantification of the percentage of area positively stained 
by WGA per image. C, quantification of the fluorescence intensity of WGA. Values are presented as fold control of 
mean ± SEM. Values sharing the same letter are not significantly different (p < 0.05): a indicates different from CON; 
c indicates different from HUL; d indicates different from CONL. 
 
 
 
 
 
induced production of reactive oxygen species would be reduced, primarily via Nox2 
inhibition, by daily losartan administration. Soleus muscle cross-sections were incubated 
with dihydroethidium (DHE) to assess superoxide production. We found a significant 
rise in the number of nuclei positively stained with ethidium in HU cross-sections 
compared to the CON muscles (p < 0.0001) (Figure 3.8). In addition, we observed a 
significant protection offered by losartan treatment during unloading (p = 0.0416). 
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However, HUL still contained a significantly greater amount of ethidium positive nuclei 
compared to CON and CONL (p = 0.0001 and p = 0.0091, respectively).  
 
 
 
 
Figure 3.8. Hindlimb unloading leads to a rise in superoxide production. A, representative images of soleus 
muscle sections that were incubated with dihydroethidium (DHE) to indicate superoxide production. Scale bar = 100 
µm. B, quantification of nuclei positively stained with ethidium. Values are presented as fold control of mean ± SEM. 
Values sharing the same letter are not significantly different (p < 0.05): a indicates different from CON; c indicates 
different from HUL; d indicates different from CONL. 
 
 
Given that the hindlimb unloading-induced elevation in superoxide production 
was mitigated by losartan treatment and previous findings have observed that AT1R 
blockade ameliorates NADPH oxidase accumulation and production of superoxide, we 
measured the protein content of Nox2 subunits in the membrane fraction of the soleus 
muscle fibers. Western blot experiments showed a significantly greater content of the 
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membrane-bound gp91phox Nox2 subunit in HU samples compared to CON (p = 
0.0105) (Figure 3.9). This effect was prevented by losartan treatment during HU with 
only a 28% rise in gp91phox content compared to CON, while remaining 60% lower 
than HU (p = 0.1192). Examination of sarcolemma-localized content of the 
transportable, cytosolic subunits found consistently increased trends among p67phox and 
p47phox subunits in HU compared to CON (79% and 88.7% increases, respectively) 
(Figure 3.9). In addition, a significant increase in sarcolemma content of Rac1 was 
observed in HU samples vs CON (p = 0.001) (Figure 3.9). Losartan partially prevented 
the rise in concentration of sarcolemma-localized Nox2 subunits, with each of the 
measured subunits remaining non-significantly different from CON and CONL groups. 
Due to our findings that unloading results in increased protein content of 
sarcolemma-localized Nox2 subunits, and the implication of elevated Nox2 activity, we 
then investigated whether this translated to elevated Nox2 activity. NADPH-dependent 
superoxide production was measured by lucigenin chemiluminescence in soleus muscle 
homogenates. Using NADPH as a substrate, superoxide was significantly increased by 
38.4% in HU muscles compared to CON (p = 0.0282) (Figure 3.10). In an effort to 
establish that NADPH oxidase was the main source of NADPH-dependent superoxide 
production in the HU soleus muscles, we used inhibitors of NADPH oxidase and a 
potent superoxide mimetic (EUK134). Treatment with 50 µM of EUK134 resulted in an 
almost complete abolishment of superoxide production. The general NADPH oxidase 
inhibitor DPI prevented approximately an 80% reduction of superoxide production 
across the groups, strongly suggesting that the superoxide produced was primarily due to  
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Figure 3.9. Mechanical unloading-induced alterations in NADPH oxidase isoform 2 (Nox2) protein content in 
the membrane fraction of soleus muscles. A, representative western blot detection of select Nox2 subunits in the 
soleus muscle membrane fraction. B, quantification of Nox2 western blot detection. Ponceau S Red (PR) stain (~42 
kDa mark) used as a loading control for western blotting quantification. Values are presented as fold control of mean ± 
SEM. Values sharing the same letter are not significantly different (p < 0.05): a indicates different from CON; c 
indicates different from HUL; d indicates different from CONL. 
 
 
NADPH oxidases. Use of the Nox2 specific pharmacological inhibitor gp91dstat 
resulted in more than a 50% reduction in superoxide production, suggesting Nox2 as a 
major Nox complex contributing to NADPH-dependent superoxide production. 
3.3.3 Dislocation of Sarcolemmal nNOSµ Driven by Prolonged Mechanical Unloading 
is Mitigated by AT1R Blockade. 
In the next set of experiments, we tested the hypothesis that hindlimb unloading-
induced dislocation of nNOSµ from the sarcolemma would be protected by AT1R 
blockade. Localization of nNOSµ protein was assessed by immunofluorescence staining 
which revealed a substantial reduction in sarcolemma-localized nNOSµ in HU soleus  
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Figure 3.10. AT1R blockade ameliorates NADPH oxidase superoxide production in soleus muscles from 
hindlimb unloaded rats. NADPH-dependent superoxide production was assessed by lucigenin chemiluminscence. 
Soleus muscles were pooled for each group (2 pools per group; n = 3 muscles per pooled sample). Comparison of 
superoxide production in the absence and presence of ROS inhibitors: EUK-134 (50 µM), an SOD/Catalase mimetic; 
diphenyleneiodonium (DPI; 10 µM), a non-specific NADPH oxidase inhibitor; and gp91ds-tat (5 µM), a NADPH 
oxidase isoform 2 specific inhibitor. Superoxide production was compared to the level of control without an inhibitor. 
Values are presented as fold control of mean ± SEM. Values sharing the same letter are not significantly different (p < 
0.05): a indicates different from CON; c indicates different from HUL; d indicates different from CONL. 
 
 
muscle fibers, an effect that appeared to be partially prevented by treatment with losartan 
(Figure 3.11A). To confirm the immunofluorescence observations, we performed 
subcellular fractionation and western blotting to detect membrane-localized and 
cytoplasmic localized nNOS protein (Figure 3.11B & C). HU muscles were found to 
have 52.9% less sarcolemma-localized nNOSµ than CON (p < 0.0001), whereas HUL 
muscles contained only 26.5% less, although still significantly lower than CON and 
CONL (p = 0.0121 and 0.0032, respectively) (Figure 3.11B). While cytoplasmic nNOS 
was not found to be different across groups, there was a 30% increase in cytoplasmic 
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nNOS in both the HU and HUL groups compared to CON, and a 20% increase in CONL 
compared to CON (Figure 3.11C). The ratio of cytoplasmic:membrane nNOS was 
significantly elevated in the HU group compared to CON (p = 0.0029), whereas the ratio 
in HUL soleus was not found to be significantly different from CON or CONL (Figure 
3.11D). 
 
 
 
Figure 3.11. Unloading-induced reduction of sarcolemmal neuronal nitric oxide synthase (nNOS) content in 
soleus muscle fibers is mitigated by losartan treatment. A (top row), representative immunofluorescent images of 
nNOS stained soleus muscle sections. Scale bar = 100 µm. B, western blot detection of nNOS protein content in the 
membrane fraction. C, detection of nNOS protein content in the cytosolic fraction. D, ratio of cytosolic nNOS content 
to membrane content of nNOS based subcellular fractionation and western blot data. Ponceau S Red (PR) stain (~42 
kDa mark for membrane fraction; ~38 kDa mark for cytosolic fraction) used as a loading control for western blotting 
quantification. Values are presented as fold control of mean ± SEM. Values sharing the same letter are not 
significantly different (p < 0.05): a indicates different from CON; c indicates different from HUL; d indicates different 
from CONL. 
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Next we examined whether or not the displacement and reduction of sarcolemma 
nNOSµ extended towards an alteration in nNOS-produced •NO. Soleus muscle cross-
sections were subjected to NADPH-diaphorase staining to determine the localization of 
active •NO in muscle fibers, as seen in Figure 3.12A. Visually, apparent differences in 
sarcolemma nNOSµ activity were easily noticeable between CON and HU. 
Determination of the percentage of NADPH diaphorase-positive staining along the 
sarcolemma revealed a similar decrement in nNOSµ activity in HU vs CON (p < 0.0001) 
(Figure 3.12B) as that found in the nNOSµ membrane localization experiments (Figure 
3.11). Interestingly, losartan administration during HU maintained sarcolemma-
associated nNOSµ activity near control levels (49% vs 52.96%; p = 0.6897), which was 
dramatically higher than HU (p < 0.0001) (Figure 3.12B). 
 
 
 
 
 
 
 
Figure 3.12. Unloading-induced reduction of active sarcolemmal nNOS in soleus muscle fibers is mitigated by 
losartan treatment. A (top row), representative images of soleus muscle sections subjected to NADPH-diaphorase 
(NADPH-dia) histochemical assay to detect sarcolemmal nNOS activity taken at 10x magnification; (bottom row), 
NADPH-dia images taken at 40x magnification. Scale bar = 100 µm. B, quantification of NADPH-dia reactive 
staining found at the sarcolemma. Presented as percentage of cross-sectional circumference (CSC) that is stained 
positive. Values are means ± SEM. Values sharing the same letter are not significantly different (p < 0.05): a indicates 
different from CON; c indicates different from HUL; d indicates different from CONL. 
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3.3.4 AT1R Blockade Significantly Lessens the Unloading-Induced Nuclear 
Accumulation of FoxO3a. 
Important regulators of skeletal muscle atrophy with disuse include FoxO3a and 
p53 transcription factors. Our lab and others have previously shown that 
dephosphorylation and activation of FoxO3a was dependent on nNOSµ dislocation from 
the sarcolemma (Suzuki et al., 2007; Lawler et al., 2014). Given that losartan mitigated 
nNOSµ translocation and alterations in sarcolemmal nNOSµ activity, we tested the 
hypothesis that losartan would lead to a reduction in nuclear FoxO3a. Co-localization of 
positively stained FoxO3a myonuclei with DAPI demonstrated a dramatic rise (> 50%) 
in nuclear-localized FoxO3a in HU soleus vs CON (p < 0.0001) (Figure 3.13A & B). 
This effect was ameliorated in HUL muscles with only a 20% increase vs CON, and 
45% lower than HU (p < 0.0001). However, HUL still contained a significantly greater 
amount of positively stained FoxO3a nuclei compared to CON and CONL (p = 0.6897 
and 0.742, respectively). Further confirmation of hindlimb unloading-induced nuclear 
translocation of FoxO3a was observed with western blotting of the nuclear fraction 
(Figure 3.13C). HU displayed a drastic 770% increase in FoxO3a nuclear content 
compared to CON (p = 0.0003). HUL remained 655% lower than HU in FoxO3a nuclear 
content (p = 0.0019). Blot data did not find a significant elevation in FoxO3a nuclear 
content between HUL, CON and CONL. 
In addition to FoxO3a, p53 has been found at increased concentrations and 
activity levels as a transcription factor during the early stages of disuse (Fox et al., 
2014). We probed the nuclear fraction of soleus muscles to assess p53 content. Similar  
 56 
 
 
 
Figure 3.13. Nuclear localization of FoxO3a due to hindlimb unloading disuse is partially prevented by losartan 
administration. A, soleus muscle cross-sections stained with (top row) FoxO3a, (second row) DAPI, (third row) 
beta-sarcoglycan (b-SG), and the bottom row is comprised of the merged images. Scale bar = 100 µm. B, graphical 
representation of the percentage myonuclei positively stained for FoxO3a. Values are means ± SEM. C, detection of 
FoxO3a via western blotting in the nuclear fraction. Ponceau S Red (PR) stain (~42 kDa mark) used as a loading 
control for western blotting quantification. Values are presented as fold control of mean ± SEM. Values sharing the 
same letter are not significantly different (p < 0.05): a indicates different from CON; c indicates different from HUL; d 
indicates different from CONL. 
 
 
to the hindlimb unloading-induced increase in FoxO3a nuclear content, we observed a 
significant 310% increase in HU p53 nuclear content compared to CON (p < 0.0001) 
(Figure 3.14). In contrast to the FoxO3a nuclear content, HUL muscles were found to 
have a significant elevation of nuclear p53 compared to CON and CONL (p = 0.0003 
and p < 0.0001, respectively). These data indicate that losartan may be interfering with 
select atrophy pathways with mechanical unloading, independent of p53 signaling. 
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Figure 3.14. Nuclear content of the atrophy-inducing transcription factor p53 is dramatically increased 
following 7 days of hindlimb unloading, even in losartan-treated animals. A, western blot detection of p53 in the 
nuclear fraction of soleus muscles. Ponceau S Red (PR) stain (~42 kDa mark) used as a loading control for western 
blotting quantification. Values are presented as fold control of mean ± SEM. Values sharing the same letter are not 
significantly different (p < 0.05): a indicates different from CON; c indicates different from HUL; d indicates different 
from CONL. 
 
 
3.4 Discussion 
In this study, administration of the angiotensin II type 1 receptor (AT1R) blocker 
losartan during hindlimb unloading attenuated the disuse-induced phenotypic alterations 
including reductions in soleus muscle fiber CSA and the slow-twitch to fast-twitch fiber 
type shift. These effects were due in part to abrogation of the mechanical unloading-
induced rise in ROS levels and the accumulation and activation of Nox2. In addition, 
losartan treatment during unloading was associated with a significant protection against 
the unloading-induced dislocation of nNOS from the sarcolemma. Furthermore, losartan 
treatment also significantly reduced the nuclear accumulation of the atrophy-associated 
transcription factor FoxO3a, which has been observed to be regulated in part by 
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displaced nNOSµ. In the following paragraphs we provide a discussion of the principle 
findings. 
3.4.1 Renin Angiotensin System (RAS) and Hindlimb Unloading-Induced Atrophy 
Elevated AngII levels cause skeletal muscle wasting, and the use of angiotensin 
converting enzyme (ACE) inhibitors and / or AT1R antagonists have proven effective 
against muscle wasting (Sukhanov et al., 2011; Cabello-Verrugio et al., 2012a). For 
instance, AT1R blockade using losartan ameliorated the exacerbation of disuse atrophy 
in sarcopenic mouse muscle (Burks et al., 2011). In addition, a recent report found that 
treatment with the AngII antagonistic renin-angiotensin system peptide, Ang-(1-7), 
offered significant protection against atrophy due to limb immobilization (Morales et al., 
2016). However, there is little evidence concerning circulating AngII levels during 
disuse. In the mechanical ventilation model of disuse, Kwon et. al (2015) reported a 
significant rise in plasma AngII after 12 hours of ventilation (Kwon et al., 2015).  
Moreover, in the hindlimb unloading model, plasma AngII levels are significantly 
increased and peak at 7 days before returning to baseline levels (Chung et al., 2012). 
Other than inhibiting AngII – AT1R binding, losartan may be exerting protective effects 
as a byproduct of AT1R antagonism which leads to an increase in circulating levels of 
Ang-(1-7) (Schindler et al., 2007). In skeletal muscle, Ang-(1-7) will bind to the Mas 
receptor and promote Akt activation, thereby inhibiting UPP signaling (Cisternas et al., 
2015; Morales et al., 2016). Interestingly, evidence indicates that ligands other than 
AngII can activate AT1R signaling (Zou et al., 2004); however the identity of those 
ligands still remain unknown. 
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3.4.2 AT1R Blockade Mitigated the Disuse-Induced Morphological Changes. 
Losartan treatment has previously been shown to prevent the reduction in 
myofiber CSA following 21 days of limb immobilization via stapling in aged mice 
(Burks et al., 2011). Furthermore, Ang-(1-7), a downstream fragment of AngII via 
ACE2 (angiotensin converting enzyme II), reportedly inhibits casting-induced reductions 
of fiber CSA in the tibialis anterior following 2 weeks of immobilization by way of 
signaling through the G-protein Mas receptor (Morales et al., 2016). Our findings 
indicate that hindlimb unloading-induced muscle fiber atrophy (Figure 3.5) and fiber-
type shift (Figure 3.6) were limited by daily administration of losartan following one 
week of unloading. Interestingly, we found losartan treatment during unloading 
prevented atrophy of Type I but not Type II fibers. To our knowledge, demonstration of 
a fiber type-specific expression pattern of AT1R has not been shown, and future studies 
will need to address this issue. While losartan administration offered partial protection 
against the unloading-induced decrease in muscle fiber CSA and fiber type shift, it did 
not protect against loss of soleus mass (Table 3.1). This finding may be explained in part 
by the impact of AT1R blockade on the prevention of extra-myocyte build-up in the 
soleus muscle, as shown in Figure 3.7. In support of this observation, AT1R antagonism 
using losartan ameliorates skeletal muscle fibrosis and extra-myofiber accumulation due 
to disuse, injury, (Burks et al., 2011) and CTGF overexpression (Cabello-Verrugio et al., 
2012b). Altogether, daily losartan treatment during unloading helped mitigate the 
reduction in Type I fiber CSA, fiber type shift, and the accumulation of extra-myocyte 
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tissue, thus favoring a healthier, more functional muscle phenotype, even though total 
soleus mass was still reduced.  
3.4.3 Hindlimb Unloading-Associated Rise in ROS is Partially Prevented by Daily 
Losartan Treatment. 
Data presented here is consistent with theories suggesting the importance of 
elevated ROS during disuse atrophy. We observed an unloading-induced rise in 
superoxide as assessed by ethidium-positive nuclei in soleus muscle cross-sections 
(Figure 3.8). Additionally, we found increased superoxide production in a lucigenin 
chemiluminescence assay when NADPH was presented as a substrate in tissue 
homogenates (Figure 3.10). Using general and specific inhibitors, our data indicate that 
a major source of superoxide when NADPH was present was NADPH oxidase (Figure 
3.10). Moreover, we observed unloading-induced increases in sarcolemma content of 
NADPH oxidase isoform 2 (Figure 3.9). Increased content of the membrane-bound 
subunit gp91phox indicates elevated expression of this subunit, while increased 
abundance of sarcolemma-localized cytoplasmic subunits (i.e., p67phox, p47phox, and 
rac-1) suggest increased activity of the complex (Figure 3.9). Skeletal muscle Nox 
activity has become predominately known for its actions in response to contractile 
activity in healthy (Pearson et al., 2014) as well as dystrophic muscle (Whitehead et al., 
2010). However, elevated expression of Nox2 subunits and Nox activity has also been 
observed in plantaris muscle atrophy in response to myocardial infarction (Bechara et 
al., 2014), implicating a role for Nox complexes and Nox2 in muscle atrophy. Moreover, 
our current findings along with our previous observations (Lawler et al., 2014) indicate 
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that hindlimb unloading can lead to increased expression and activation of sarcolemma-
localized Nox2 subunits. In connection with those findings, Bhattacharya et al. (2014) 
observed increased Nox activity in gastrocnemius muscles from denervated mice 
(Bhattacharya et al., 2014). Together, these data indicate that Nox2 and Nox-derived 
superoxide are responsive not only to activity (i.e., skeletal muscle contraction) but also 
to prolonged periods of inactivity (i.e., disuse) and the general atrophic process. 
Our current observation that administration of the AT1R blocker losartan 
reduced the unloading-induced increase in superoxide and Nox2 subunits (Figures 3.8 – 
3.10) is in agreement with findings from previous studies. While the AT1R – Nox 
connection has been shown previously in a variety of tissues, including skeletal muscle 
(Sukhanov et al., 2011), we are the first to report this connection during disuse atrophy. 
For example, L6 myotubes treated with AngII displayed increased Nox activity and 
subsequent ROS production, effects that were mitigated by the Nox inhibitor, apocynin 
and the AT1R antagonist, losartan (Wei et al., 2006). Furthermore, elevated ROS levels 
in skeletal muscle were detected in rats treated with AngII, an effect that coincided with 
an up-regulation of gp91phox (Zhao et al., 2006). In relation to skeletal muscle wasting, 
Semprun-Prieto et al. (2011) observed that AngII-induced atrophy was associated with 
elevated superoxide production, with both ROS production and atrophy prevented in 
p47phox-/- mice (Semprun-Prieto et al., 2011). Additional evidence shows increased 
mitochondrial ROS (Tabony et al., 2011) and mitochondrial dysfunction (Kadoguchi et 
al., 2015) following AngII administration. Interestingly, Tabony et al. (2011) found that 
inhibition of mitochondrial-derived ROS did not alter the degree of AngII-induced 
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skeletal muscle wasting (Tabony et al., 2011), indicating that AngII atrophy signaling is 
likely through Nox rather than mitochondrial ROS production. 
3.4.4 Dislocation of nNOSµ Caused by Disuse is Limited by Daily Losartan Treatment. 
Prolonged periods of disuse have been shown to result in the sarcolemma 
dislocation of the mu isoform of neuronal nitric oxide synthase (nNOSµ) (Suzuki et al., 
2007; Llano-Diez et al., 2012; Sandona et al., 2012; Lawler et al., 2014). Whether or not 
disuse leads to a reduction in nNOSµ expression remains controversial (Suzuki et al., 
2007; Lomonosova et al., 2011). We have previously reported that 54 hours of hindlimb 
unloading leads to nNOSµ translocation, coinciding with a rise in sarcolemma-
associated oxidative modifications, suggesting that elevated ROS is a causal event in 
nNOSµ translocation (Lawler et al., 2014). As expected, in the current study we 
observed that 7 days of hindlimb unloading was associated with dislocation of nNOSµ 
determined via immunofluorescence of soleus muscle cross-sections and western 
blotting following subcellular fractionation (Figure 3.11). Interestingly, losartan 
treatment throughout the unloading period offered partial protection against the 
unloading-induced nNOSµ alterations (Figure 3.11). While western blot detection of 
sarcolemmal nNOSµ found that HUL rats still had significantly less membrane-
associated nNOSµ, through NADPH-diaphorase histochemical staining to assess nNOS 
activity, HUL solei were shown to have sarcolemma nNOS activity similar to controls 
(Figure 3.12).  
Intriguing findings indicate that NOS and the resultant nitric oxide (•NO) are 
involved in the regulation of type I myosin heavy chain expression (Sellman et al., 2006; 
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Suwa et al., 2015). For example, a significant reduction in the percentage of type I fibers 
and concomitant increase in type IIa fibers were found in the rat soleus following 8 
weeks of NOS inhibition (Suwa et al., 2015). Prolonged periods of disuse are known to 
be associated with a type I to type II shift in fiber type, as we have shown here, and 
unloading nNOSµ alterations may be playing a critical role in the phenotype adaptation. 
In support of this notion, we found that losartan offered protection against unloading-
induced nNOSµ localization and activity alterations accompanied by protection against 
the shift in fiber type.  
3.4.5 Atrophy-Related Transcription Factors are Elevated with Hindlimb Unloading. 
Unloading-induced nNOSµ dislocation has also been associated with 
dephosphorylation of FoxO3a (Suzuki et al., 2007; Lawler et al., 2014), thus leading to 
shuttling of FoxO3a to the nucleus where it acts as a transcription factor for key 
atrogenes: MuRF1 and MAFbx/Atrogin 1 (Suzuki et al., 2007). Disuse atrophy is 
primarily driven by the upregulation of E3 ubiquitin ligases MuRF-1 and 
MAFbx/Atrogin-1 (Bodine et al., 2001). Expression of these two ligases is promoted by 
FoxO3a (Schiaffino et al., 2013). Activation of FoxO3a is directed by inhibition of Akt 
(Schiaffino et al., 2013) and has been shown to be sensitive to sarcoplasmic nNOS 
derived •NO (Suzuki et al., 2007). We found consistent elevation of nuclear FoxO3a, 
detected by both DAPI-localized immunofluorescence and nuclear fraction abundance 
with HU (Figure 3.13). Losartan indeed abrogated upregulation of nuclear FoxO3a and 
thus nuclear translocation and activation (Figure 3.13). This suggests that AT1R – Nox2 
signaling is important in activation of FoxO3a. Elevated levels of dephosphorylated 
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FoxO1 and FoxO3a proteins, as well as the associated transcription of the E3 ligases 
MuRF1 and MAFbx/Atrogin 1, have been observed in AngII treated mice (Tabony et 
al., 2011; Tabony et al., 2014). Our findings suggest that AT1R may be upstream of an 
atrophic pathway involving Nox2, ROS, nNOSµ dislocation and FoxO3a activation 
during mechanical unloading. 
In addition to the transcription factor actions of FoxO3a during disuse, recent 
research has implicated the tumor suppressor p53 in the early stages of disuse atrophy. 
For instance, p53 protein content has been reported to be significantly higher in the 
soleus muscle during hindlimb unloading within the first 6 hours of disuse (Ferreira et 
al., 2008). Furthermore, p53 is significantly elevated with 3 days of disuse (Fox et al., 
2014), but whether this occurrence lasts beyond 3 days remains unknown. Here, we have 
shown that p53 protein is significantly elevated in the nuclear fraction of soleus muscles 
following 7 days of unloading (Figure 3.14). Unlike our FoxO3a observations, the 
unloading-induced rise in nuclear p53 was not ameliorated by losartan treatment (Figure 
3.14). Previous studies using cancer cells have reported that losartan had no effect (Xiao 
et al., 2015) or even led to an increase (Gong et al., 2010) in p53 expression. 
Interestingly, active p53 has been associated with promoting local renin-angiotensin 
system (RAS) activity in cardiac myocytes in response to stretch (Leri et al., 1998). 
Local RAS signaling has also been observed in C2C12 skeletal muscle cells in response 
to stretch (Johnston et al., 2011), but the authors did not examine p53 involvement. 
Whether p53 enhances local RAS signaling in vivo or in response to disuse in skeletal 
muscle remains unknown. Given that p53 was upstream and suppressed spermine 
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oxidase (Bongers et al., 2015), it is possible that p53 acts upon a metabolic pathway 
contributing to disuse atrophy, and AT1R – Nox2 signaling may be integrated into an 
independent mechanotransductive pathway.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
4.1 Summary and Conclusions 
As discussed in Chapter II, elevated ROS during disuse can lead to a stressful 
environment in skeletal muscle fibers, resulting in decreased rates of protein synthesis 
and increased rates of degradation. Currently, the field of disuse atrophy research lacks a 
complete understanding of the specific upstream signaling events triggering the various 
sources of ROS.  In addition, the specific regulatory actions downstream of the rise in 
levels of ROS, such as the mechanistic events leading to the untethering of sarcolemmal 
nNOSµ and activation of pro-atrophic transcription factors, are still an enigma. 
 In Chapter III we presented findings demonstrating that AT1R blockade during 7 
days of hindlimb unloading mitigates the extent of hindlimb unloading-induced soleus 
muscle atrophy (summarized in Figure 4.1). Indeed, disuse-induced reductions in fiber 
CSA, shift in fiber type, and connective tissue accumulation were limited by daily 
losartan administration. Additionally, disuse-associated elevations in ROS were 
attenuated by losartan treatment, which was in part due to a reduction in content and 
activity of NADPH oxidase 2 (Nox2). Furthermore, nNOSµ dislocation from the 
sarcolemma to the sarcoplasm due to prolonged disuse was partially prevented by 
losartan, as was the reduction in sarcolemmal nNOSµ activity. Finally, antagonism of 
AT1R during unloading ameliorated the rise in nuclear content of FoxO3a but not p53. 
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Figure 4.1. Model of the influence of AT1R activation during hindlimb unloading-induced atrophy. 
 
 
Our experiments from Chapter III reveal discoveries that are integral towards the 
unraveling of upstream factors promoting ROS production during hindlimb unloading 
atrophy. Activation of AT1R appears to be a critical step in stimulating Nox2 activity 
and accumulation during mechanical unloading. Refer to Figure 4.2 for an illustration of 
how the current findings fit into the scheme of disuse ROS-associated events.  
4.2 Clinical Relevance 
 Preventing, limiting, or delaying disuse muscle atrophy is a critical biomedical 
issue with application to spaceflight, casting, bed rest, orthopedic injuries, denervation  
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Figure 4.2. Updated version of Figure 2.2. The findings gleaned from the study presented in Chapter III where we 
observed the involvement of AT1R activation in the regulation of Nox2-ROS production are now added to an 
illustration depicting critical signaling pathways controlling muscle fiber size during disuse-induced atrophy and the 
regulatory schemes exerted by ROS. The combination of reactive oxygen species (ROS) derived from mitochondria, 
NADPH oxidase isoform 2 (Nox2), and xanthine oxidase (XO) results in an increased ROS concentration in 
myofibers during periods of disuse. Elevated ROS can blunt Akt-mTORC1 protein synthesis signaling, induce 
dislocation of nNOS from the DGC towards the sarcoplasm, enhance dephosphorylation of FoxO1/3a, and promote 
NFkB signaling. In addition, ROS from Nox2 and/or mitochondria may promote a ROS-induced ROS-release 
amplification scheme (as shown by the dashed red-lines with arrowheads). ROS regulatory functions are shown with 
red lines. Dashed lines indicate hypotheses concerning signaling events made by the authors based on published 
research findings. This is a simplified figure illustrating ROS-regulation of disuse fiber atrophy, refer to text for brief 
discussions on alternative pro-degradation routes (e.g. calpains, caspase-3, autophagy-lysosomal). 
 
 
and other effectors of skeletal muscle disuse. To our knowledge, our study presented in 
Chapter III is the first to examine the effectiveness of losartan treatment on disuse 
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atrophy with administration starting less than one week prior to the onset of disuse. Still 
unknown is whether losartan would be capable of offering protective effects if 
administration began after the onset of disuse, which would be an important discovery 
since many instances of forced bed rest, limb casting, etc., are unplanned events. 
Notably, data presented here further supports the effectiveness of AT1R blockade in 
limiting or possibly delaying disuse atrophy, providing additional rationale for the usage 
of a cost-effective and FDA-approved pharmaceutical agent (losartan) during prolonged 
periods of disuse. 
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APPENDIX 
 
Justification for the Dosage of Losartan 
In the present study, rats that received losartan were administered a dose of 30-40 
mg/kg/day via intraperitoneal (i.p.) injection. The rationale for using this concentration 
of losartan is based on the dose used in previous myopathy studies (Habashi et al., 2006; 
Cohn et al., 2007; Burks et al., 2011), which used dosages that achieved a 10 – 20% 
decrease in heart rate and blood pressure, measurements that are deemed desirable in 
humans (Habashi et al., 2006). When normalized to standard body surface area (BSA), 
30-40 mg/kg dosage for a 300 gram rat translates to an approximate dose of 6-8 
mg/kg/day in humans (Reagan-Shaw et al., 2008).  
Due to differences in drug absorption, metabolism, and elimination, larger doses 
are required in order to achieve similar pharmacological effects to those that are 
observed in humans (Mordenti, 1986). Several previously published studies have 
administered 40 mg/kg/day of losartan in adult rats without any toxic effects reported 
(Zhu et al., 2000; Zhu et al., 2003; Goncalves et al., 2005; Quigley et al., 2015). 
Additionally, 30-40 mg/kg dosage is far below the 2000 mg/kg dose that led to 
significant lethality in adult rats (Merck, 2015). Therefore, the dosage of losartan used in 
the present study is a non-toxic and translatable amount. 
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Table A1. Primary Antibodies 
Antibody Dilution Company Catalog # Experiment 
GAPDH 1:10,000 EMD/Millipore MAB374 Western Blotting 
Na+/K+ ATPase 1:1,000 Cell Signaling 
Technology 
05-369 Western Blotting 
Histone H3 1:1,000 Cell Signaling 
Technology 
9715 Western Blotting 
gp91phox 1:1,000 BD Biosciences 611415 Western Blotting 
p67phox 1:2,500 BD Biosciences 610913 Western Blotting 
p47phox 1:750 BD Biosciences 610355 Western Blotting 
Rac-1 1:500 EMD/Millipore 07-1464 Western Blotting 
nNOS 1:750 Life Technologies 
/ Thermo Fisher 
Scientific 
61-700 Western Blotting 
FoxO3a 1:750 Cell Signaling 
Technology 
12829 Western Blotting 
p53 1:750 Cell Signaling 
Technology 
2527 Western Blotting 
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Table A1. Primary Antibodies (continued) 
Antibody Dilution Company Catalog # Experiment 
Dystrophin 1:100 Santa Cruz 
Biotechnology 
sc-15376 Immunofluorescence 
Slow Skeletal 
Myosin 
1:250 Abcam ab11083 Immunofluorescence 
Fast Skeletal 
Myosin 
1:250 Abcam ab51263 Immunofluorescence 
β-Sarcoglycan 1:200 Abcam ab55683 Immunofluorescence 
nNOS 1:100 Cayman 
Chemical 
160870 Immunofluorescence 
FOXO3a 
(FKHRL1) 
1:50 Sigma SAB3500
508 
Immunofluorescence 
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Table A2. Secondary Antibodies 
Antibody Dilution Company Catalog # Experiment 
Goat Anti-Rabbit 
IgG-HRP 
1:5,000 Santa Cruz 
Biotechnology 
sc-2004 Western Blotting 
Goat Anti-Mouse 
IgG-HRP 
1:5,000 Santa Cruz 
Biotechnology 
sc-2005 Western Blotting 
     
Goat Anti-Rabbit 
IgG (H+L) 
Secondary 
Antibody, Alexa 
Fluor 594 
conjugate 
1:200 Life Technologies 
/ Thermo Fisher 
Scientific 
A-11037 Immunofluorescence 
Goat-Anti-Mouse 
IgG (H+L) 
Secondary 
Antibody, Alexa 
Fluor 594 
conjugate 
1:200 Life Technologies 
/ Thermo Fisher 
Scientific 
A-11005 Immunofluorescence 
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Table A2. Secondary Antibodies (continued) 
Antibody Dilution Company Catalog # Experiment 
Goat Anti-Rabbit 
IgG (H+L) 
Secondary 
Antibody, Alexa 
Fluor 488 
conjugate 
1:200 Life Technologies 
/ Thermo Fisher 
Scientific 
A-11008 Immunofluorescence 
Goat-Anti-Mouse 
IgG (H+L) 
Secondary 
Antibody, Alexa 
Fluor 488 
conjugate 
1:200 Life Technologies 
/ Thermo Fisher 
Scientific 
A-11001 Immunofluorescence 
 
 
 
 
 
 
 
 
 91 
 
Table A3. Injectable Reagents 
Reagent Company Catalog # 
Ketamine Henry Schein 045822 
Xylazine Lloyd (from Henry Schein) 033198 
Somnasol – Euthanasia III Solution 
(Pentobarbital Sodium) 
Henry Schein 024352 
Losartan (potassium salt)  Cayman Chemical 10006594 
0.9% Sodium Chloride (Saline) Injection, 
USP 
Hospira 0409-7984 
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Table A4. Buffer Reagents 
Reagent Company Catalog # 
Tris-HCl (Trizma hydrochloride) Sigma-Aldrich T5941 
NaCl (sodium chloride) Sigma-Aldrich S9625 
EDTA (ethylenediaminetetraacetic acid) Sigma-Aldrich ED 
EGTA (ethylene glycol-bis(2-
aminoethylether)-N,N,N’,N’-tetraacetic 
acid) 
Sigma-Aldrich E3889 
Sucrose Sigma-Aldrich S-7903 
MgCl2 (magnesium chloride hexahydrate) Sigma-Aldrich M-2670 
HEPES Sigma-Aldrich H4034 
Glycerol Sigma-Aldrich G5516 
Triton X-100 MP Biomedicals 194854 
Tween-20 Thermo Fisher Scientific P1379 
NBT (nitrotetrazolium blue chloride) Sigma-Aldrich N6639 
Beta-NADPH (β-nicotinamide adenine 
dinucleotide 2’-phosphate reduced 
tetrasodium salt hydrate) 
Sigma-Aldrich N7505 
Protease Inhibitor Cocktail Mini Tablets; 
EDTA-free 
Thermo Fisher Scientific 88666 
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Table A5. Western Blotting Reagents 
Reagent Company Catalog # 
Non-fat dry milk  Carnation  
Ponceau S  Sigma-Aldrich P3504 
Bradford Dye Reagent Concentrate Bio-Rad 500-0006 
Super Signal West Dura Extended 
Duration Substrate 
Thermo Fisher Scientific 34076 
Precision Plus Protein Kaleidoscope 
Standards 
Bio-Rad 161-0375 
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Table A6. Histochemistry Reagents 
Reagent Company Catalog # 
O.C.T. (Optimal Cutting Temperature) 
Compound 
Fisher HealthCare 4585 
Hematoxylin VWR 95057-844 
Eosin VWR 95057-846 
Wheat Germ Agglutinin, Alexa Fluor 555 
Conjugate 
Life Technologies / 
Thermo Fisher Scientific 
W32464 
DAPI (4’,6-Diamidino-2-Phenylindole, 
Dihydrochloride) 
Life Technologies / 
Thermo Fisher Scientific 
D1306 
Normal Goat Serum (10%) Blocking 
Solution 
Life Technologies / 
Thermo Fisher Scientific 
50062Z 
VectaMount Permanent Mounting Medium Vector Laboratories H-5000 
ProLong Gold Anti-Fade Mountant Life Technologies / 
Thermo Fisher Scientific 
P36930 
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Table A7. Reactive Oxygen Species (ROS) Detection and Inhibition Reagents 
Reagent Company Catalog # 
Dihydroethidium (DHE) Life Technologies 
/ Thermo Fisher 
Scientific 
D1168 
Lucigenin Cayman Chemical 14872 
EUK 134 Cayman Chemical 10006329 
Diphenyleneiodonium 
Chloride (DPI) 
Sigma-Aldrich D2926 
gp91dstat Bio-synthesis, Inc. Custom: 
[NH2]YGRKKRRQRRRCSTRIRRQL[CONH2] 
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NOMENCLATURE 
 
4E-BP1 4E-Binding Protein 1 
ACE Angiotensin Converting Enzyme 
ALS Amyotrophic Lateral Sclerosis 
AngII Angiotensin II 
Ang-1(1-7) Angiotensin-1(1-7) 
AT1R Angiotensin II Type 1 Receptor 
ATF4 Activating Transcription Factor 4 
BSA Body Surface Area 
COPD Chronic Obstructive Pulmonary Disease 
CSA Cross-Sectional Area 
CSC Cross-Sectional Circumference 
DETC Diethyl-Dithiocarbamate 
DGC Dystrophin Glycoprotein Complex 
DHE Dihydroethidium 
DPI Diphenyleneiodonium 
EUK134 Eukaryion 134 
Fn14 Fibroblast Growth Factor-Inducible 14 
FoxO Forkhead Members of the Class O 
GR Glucocorticoid Receptor 
Grp94 Glucose-Regulated Protein 94 
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HSP Heat Shock Protein 
IGF-1 Insulin-Like Growth Factor-1 
IGFR Insulin-Like Growth Factor Receptor 
IκB Inhibitor of Kappa B 
iNOS Inducible Nitric Oxide Synthase 
i.p. Intraperitoneal 
IRS-1 Insulin Receptor Substrate-1 
MAFbx Muscle Atrophy F-Box 
MG53 Mitsugumin 53 
MGD N-Methyl-D-Glucamine-Dithiocarbamate 
MHC Myosin Heavy Chain 
mTORC1 Mammalian Target of Rapamycin Complex 1 
Mul1 Mitochondrial E3 ubiquitin ligase 1 
MuRF1 Muscle Specific RING Finger Protein 1 
MUSA1 Muscle Ubiquitin Ligase of SCF Complex in Atrophy - 1 
NADPH  Nictotinamide Adenine Dinucleotide Phosphate  
Nox NADPH Oxidase 
NFκB Nuclear Factor Kappa B 
nNOS Neuornal Nitric Oxide Synthase 
•NO  Nitric Oxide 
PI3K Phosphatidylinositol-3 Kinase 
RAS Renin-Angiotensin System 
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ROS Reactive Oxygen Species 
SEM Standard Error Mean 
TRIM72 Tripartite Motif 72 
ULLS Unilateral Lower Limb Suspension 
UPP Ubiquitin Proteasome Pathway 
WGA Wheat Germ Agglutinin 
XO Xanthine Oxidase 
